Perioperative on Dual Brain Lab

Esophageal Cancer Trial Timeline: A Dual-Track Map of 30 Years and 42 RCTs

Tue, 21 Apr 2026 00:00:00 +0000

Esophageal Cancer Clinical Trial Timeline — In-Depth Report

Coverage: 42 NCCN Esophageal-cited landmark trials (all PMID-traceable) + ESCC / EAC dual-track evolution + East–West perioperative divergence + post-IO 2L unmet need

Curated by Dual Brain Lab (csilab.net)

1. One-sentence definition

This report traces the evolution and current decision landscape of esophageal cancer (EC) systemic + local therapy over the past 30 years (1992–2024), using the landmark clinical trials cited in the current NCCN Esophageal guideline, so that frontline clinicians in 2026 have a traceable, whole-picture map for the “who, what, and why” of treatment decisions.

Iron rule: every data point on every trial traces back to PubMed (PMID) or ClinicalTrials.gov (NCT id) — every [PMID xxxxxxxx] bracket in the body can be opened directly on PubMed for verification.

EC’s uniqueness clusters around one divide: by histology, into squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) — ESCC is >85% globally and >90% in Asia, while EAC dominates in North America and Western Europe; gastroesophageal junction (GEJ) adenocarcinoma is anatomically and epidemiologically closer to gastric cancer, and the EC scope of this report covers the esophagus proper only (with some Siewert I/II mixed enrollment in the original CROSS / CheckMate-577 cohorts). Clinical decisions cross three axes: resectability (early / locally advanced / advanced) × histology (ESCC RT-sensitive / EAC chemo-sensitive) × biomarker (PD-L1 CPS / TAP / TC% — the three scores are non-interchangeable across trials, an ESCC-specific pain point).

Unlike NSCLC with its dozen-plus molecular strata (EGFR / ALK / ROS1 / KRAS / PD-L1), EC has no approved targetable driver: HER2-positive adenocarcinoma follows the gastric path (ToGA / DESTINY-Gastric01), the EGFR panitumumab POWER trial in ESCC was terminated early, and EC relies entirely on the three-pillar combination of chemo backbone + PD-1/PD-L1 IO + RT.

2. Longitudinal: five paradigm shifts along the timeline

EC treatment over the past 30 years has gone through five paradigm shifts: 1992–2007 definitive CRT established → 2012 CROSS anchored global neoadjuvant CRT → 2018–2024 East Asian ESCC path divergence (China NEOCRTEC5010 + Japan JCOG1109 DCF) → 2021+ advanced IO big three explosion → 2021+ IO enters the perioperative setting. Each shift rests on 1–3 phase III trials as fulcrums.

Compared with NSCLC’s “driver-gene + immunotherapy dual engine,” EC’s evolution is characterized by “chemo + RT + IO three-pillar combinations + East–West path divergence” — no predictive biomarker (other than PD-L1, and its three scores are not interchangeable). This resembles HCC’s “0-biomarker IO backbone,” but EC adds one more axis: East Asian ESCC vs Western EAC geographic divergence.

2.1 Definitive CRT era established (1992–2007): making “no surgery” an option, and the dose paradox

Story: before 1992, local treatment for ESCC = RT alone or radical surgery (perioperative mortality 10%). RTOG 85-01 used 50 Gy + CF to push 2-year OS from 10% to 38%, and 5-year follow-up from 0% to 26% — establishing concurrent def-CRT as a curative option. Later, INT 0123 tried dose escalation to 64.8 Gy and found OS worse, creating the counterintuitive rule that “50.4 Gy is the global def-CRT dose ceiling”; in 2007, FFCD 9102 further showed that among induction-CRT responders, “adding surgery vs continuing CRT” yielded no 2y OS difference (but perioperative mortality was 9.3% vs 0.8%) — the organ-preservation logic was born.

RTOG 85-01 [PMID 1584260] (Herskovic 1992 N Engl J Med, N=121): concurrent cisplatin+5FU × 4 cycles + 50 Gy vs RT alone at 64 Gy. 2-year OS 38% vs 10% (p<0.001), stopped early. Concept born: concurrent def-CRT is a curative option; concurrent AEs rose markedly but were outweighed by the survival gain.
RTOG 85-01 long-term [PMID 10235156] (Cooper 1999 JAMA): 5-year follow-up. 5-year OS 26% vs 0% (p<0.0001). First proof that def-CRT can cure a meaningful fraction of EC without surgery — defining “RT 50 Gy + CF doublet” as the ESCC def-CRT backbone for the next 30 years.
FFCD 9102 [PMID 17401004] (Bedenne 2007 J Clin Oncol, N=259): induction-CRT responders randomized to “continue CRT to 66 Gy vs add surgery.” 2y OS 34% vs 40% (HR 0.90, NS); 3-month perioperative mortality 9.3% vs 0.8% (p=0.002). Organ-preservation logic: responders need not add surgery — but only for induction-CRT responders; non-responders still need salvage surgery.

Takeaway: the two RTOG / FFCD generations in 1992–2007 established the three pillars of ESCC def-CRT: (1) 50 Gy + CF doublet is the dose ceiling (INT 0123 at 64.8 Gy was worse; all later Western trials kept 50–50.4 Gy as the gold standard); (2) in responders, def-CRT can replace surgery, especially in high-surgical-risk patients, high-cervical tumors, or those who refuse surgery; (3) salvage esophagectomy after def-CRT failure remains feasible (see §2.5 FREGAT cohort).

2.2 Global neoadjuvant CRT (2012–2018): CROSS rewrote the world + East Asia split off

Story: in 2012, the Dutch CROSS trial used weekly carboplatin+paclitaxel × 5 + 41.4 Gy to push mOS from 24.0 to 49.4 months (HR 0.657), with pCR 29% and R0 92% — anchoring the global neoadjuvant CRT paradigm. CROSS long-term (2015) and the 10-year follow-up (2021) kept validating it (SCC subgroup HR 0.48, far stronger than AC). In 2018, China’s NEOCRTEC5010 used vinorelbine+cisplatin × 2 + 40 Gy/20 fx (Western dose + Chinese chemo regimen) with mOS 100.1 vs 66.5 months (HR 0.71), pCR 43.2% — the Chinese ESCC neoadjuvant standard was born, standing alongside CROSS.

CROSS primary [PMID 22646630] (van Hagen 2012 N Engl J Med, N=366, Netherlands, 75% EAC / 23% ESCC): neoadjuvant weekly carboplatin AUC 2 + paclitaxel 50 mg/m² × 5 + 41.4 Gy/23 fx → surgery vs surgery alone. mOS 49.4 vs 24.0 months (HR 0.657, p=0.003), R0 92% vs 69%, pCR 29%. Global paradigm anchor — all Western EC perioperative trials since have used CROSS as the comparator.
CROSS long-term [PMID 26254683] (Shapiro 2015 Lancet Oncol, N=366): benefit sustained at 7-year median follow-up (HR 0.68). SCC subgroup HR 0.48 — the squamous effect is much stronger than adenocarcinoma (even though only 84 SCC patients). This SCC/AC subgroup gap later directly justified choosing between def-CRT and neoadjuvant CRT in ESCC.
CROSS 10-year [PMID 33891478] (Eyck 2021 J Clin Oncol, N=366): 10-year absolute OS gain of 13% (38% vs 25%). Locoregional relapse HR 0.40 stable over time — long-term local control is CROSS’s most robust signal.
JCOG9907 [PMID 21879261] (Ando 2012 Ann Surg Oncol, N=330, Japan, 100% ESCC): post-op CF vs pre-op CF × 2 cycles. 5y OS 55% (preop) vs 43% (postop), HR 0.73, p=0.04. Japan’s ESCC SoC became “pre-op CF doublet”, diverging from the Western CRT path. JCOG’s subsequent work stayed on the “pre-op chemo” track (ultimately evolving into 2024 JCOG1109’s DCF triplet).
NEOCRTEC5010 [PMID 30089078] (Yang 2018 J Clin Oncol, N=451, China, 100% ESCC): neoadjuvant vinorelbine 25 mg/m² d1,8 + cisplatin 75 mg/m² d1 × 2 cycles + 40 Gy/20 fx → surgery vs surgery alone. mOS 100.1 vs 66.5 months (HR 0.71, p=0.025), pCR 43.2%, R0 98.4%. The Chinese ESCC neoadjuvant standard was born — pCR 43.2% is one of the highest in EC perioperative history.
NEOCRTEC5010 long-term [PMID 34160577] (Yang 2021 JAMA Surg, N=451): long follow-up with 5y OS 59.9% vs 49.1% (HR 0.74, p=0.03), 5y DFS 63.6% vs 43.0% — LA-ESCC long-term curve separation held steady.
SCOPE-1 [PMID 28196063] (Crosby 2017 Br J Cancer, N=258, UK, 73% ESCC): def-CRT (cisplatin+capecitabine + 50 Gy) ± cetuximab phase II/III. Cetuximab arm closed early for futility (HR 1.25); def-CRT-only arm mOS 34.5 months. Modern Western def-CRT benchmark, and the first failed attempt at “ESCC + EGFR mAb.”
Neo-AEGIS [PMID 37734399] (Reynolds 2023 Lancet Gastroenterol Hepatol, N=377, Ireland-led): locally advanced esophageal / GEJ adenocarcinoma neo-CRT (CROSS regimen) vs perioperative chemo (MAGIC / FLOT). 3y OS 55% vs 57% (HR 1.03, 95% CI 0.77–1.38, equipoise) — CROSS and FLOT-perioperative are equivalent in EAC, the first phase III head-to-head of neoadjuvant CRT vs perioperative chemo in EAC.

Takeaway: in the 5 years 2012–2018, CROSS anchored neoadjuvant CRT for Western EC + GEJ AC, JCOG9907 anchored pre-op CF chemo for Japanese ESCC, and NEOCRTEC5010 anchored pre-op CRT for Chinese ESCC — three geographic paths branched apart. Neo-AEGIS later showed CROSS and FLOT-perioperative are equivalent in EAC, but the three ESCC paths have never been directly phase-III head-to-head compared.

2.3 Intra–East Asia ESCC divergence (2024): JCOG1109 NExT broke the “RT always helps” assumption

Story: in 2024, Japan’s JCOG1109 NExT was the first trial to compare CF doublet / DCF triplet / CF+RT in three arms within one trial. The result was DCF beat CF (HR 0.68, p=0.006); CF+RT did not beat CF (HR 0.84, NS) — apparently conflicting with China’s NEOCRTEC5010 (CRT beat surgery HR 0.71) and Europe’s CROSS (SCC subgroup HR 0.48). Possible explanation: Japan’s high-quality D2+ lymphadenectomy + intraoperative 3FL (three-field lymphadenectomy) absorbed the extra RT benefit — a hypothesis never formally tested.

JCOG1109 NExT [PMID 38876133] (Kato 2024 Lancet, N=601, Japan, 100% ESCC): three-arm RCT — NeoCF vs NeoCF+D (DCF = docetaxel+CF) vs NeoCF+RT (CF + 41.4 Gy) → surgery. 3y OS 62.6% / 72.1% / 68.3%; DCF vs CF HR 0.68, p=0.006 positive; CF+RT vs CF HR 0.84, NS — Japanese ESCC neoadjuvant SoC upgraded from CF to DCF, with no RT added.

Takeaway: 2024’s JCOG1109 NExT rewrote Japan’s ESCC neoadjuvant SoC — from CF doublet up to DCF triplet, but no RT added. This crystallized a three-country split within East Asian ESCC: China nCRT (NEOCRTEC5010) / Japan DCF triplet without RT (NExT) / Korea still mostly def-CRT. No direct head-to-head between the three paths — each country cites its own landmark. The universal clinical lesson: surgical-dissection quality, chemo intensity, and RT benefit substitute for each other, and the RT benefit may be absorbed under high-quality 3FL lymphadenectomy.

2.4 Advanced IO big three explosion (2019–2024): 4 years and 8 positive phase III trials reset SoC from CF/TP to IO+chemo

Story: in 2019, ATTRACTION-3 first pushed nivolumab 2L ESCC to positive (HR 0.77), independent of PD-L1 expression — the first global approval for 2L ESCC IO. In 2020–2022 the big three arrived the same year: KEYNOTE-590 (ESCC + EAC 1L global pembro, PMID 34454674), CheckMate-648 (pure ESCC 1L global nivo+chemo / nivo+ipi, PMID 35108470), ESCORT-1st (China camrelizumab 1L, PMID 34519801). 8 positive phase III trials in four years (plus ORIENT-15 sintilimab, JUPITER-06 toripalimab, RATIONALE-306 tislelizumab, ASTRUM-007 serplulimab, GEMSTONE-304 sugemalimab) completely reset 1L SoC from CF/TP. In the 2L battlefield, ATTRACTION-3 / KEYNOTE-181 / ESCORT / RATIONALE-302 ran in parallel, all HRs converging tightly in the 0.69–0.77 band.

ATTRACTION-3 [PMID 31582355] (Kato 2019 Lancet Oncol, N=419, East Asia-led): nivolumab vs taxane / docetaxel 2L ESCC. mOS 10.9 vs 8.4 months (HR 0.77, p=0.019). First global approval for 2L ESCC IO, independent of PD-L1 — opened the ESCC IO door.
KEYNOTE-181 [PMID 33026938] (Kojima 2020 J Clin Oncol, N=628, global, ESCC ~65% / EAC ~35%): pembrolizumab vs investigator-choice chemo 2L EC. CPS≥10 mOS 9.3 vs 6.7 months (HR 0.69, p=0.0074); SCC subgroup mOS 8.2 vs 7.1 months (HR 0.78); ITT HR 0.89 (p=0.056) negative. FDA approval restricted to CPS≥10 — set the strict PD-L1 biomarker posture. Afterward KN-590 kept CPS, CheckMate-648 used TC%, RATIONALE-306 used TAP — scoring methods started fragmenting.
ESCORT [PMID 32416073] (Huang 2020 Lancet Oncol, N=457, China): camrelizumab vs docetaxel / irinotecan 2L ESCC. mOS 8.3 vs 6.2 months (HR 0.71, p=0.001). First domestic Chinese PD-1 approval in ESCC — paved the way for the 1L ESCORT-1st combination (2021).
KEYNOTE-180 [PMID 30570649] (Shah 2019 JAMA Oncol, N=121, global): heavily pretreated EC (ESCC + EAC) pembrolizumab monotherapy phase II. ORR 9.9%, ESCC subgroup ORR 14.3% (vs EAC 5.2%) — early signal that ESCC responds to IO better than EAC, one basis for KN-590’s stratification.
KEYNOTE-590 [PMID 34454674] (Sun 2021 Lancet, N=749, global, ESCC 74% / EAC 26%): pembrolizumab + CF vs placebo + CF 1L. ESCC + CPS≥10 mOS 13.9 vs 8.8 months (HR 0.57, p<0.0001); all pts mOS 12.4 vs 9.8 months (HR 0.73). First global 1L positive phase III to include ESCC, FDA-approved 2021-03 — opened the ESCC 1L IO+chemo era.
ESCORT-1st [PMID 34519801] (Luo 2021 JAMA, N=596, China): camrelizumab + TP (paclitaxel+cisplatin) vs placebo + TP 1L ESCC. mOS 15.3 vs 12.0 months (HR 0.70, p=0.001), mPFS 6.9 vs 5.6 months. First 1L ESCC IO approval in China (NMPA 2021) — almost the same year as KN-590.
CheckMate-648 [PMID 35108470] (Doki 2022 N Engl J Med, N=970, global, pure ESCC): three arms — nivolumab + chemo / nivolumab + ipilimumab (chemo-free) / chemo 1L ESCC. TC PD-L1≥1%: nivo+chemo mOS 15.4 vs 9.1 months (HR 0.54); nivo+ipi mOS 13.7 vs 9.1 months (HR 0.64). First approved chemo-free IO+IO 1L regimen — ESCC has one chemo-free option that gastric does not, an exclusive advantage.
ORIENT-15 [PMID 35440464] (Lu 2022 BMJ, N=659, China + partial Europe): sintilimab + chemo vs placebo + chemo 1L ESCC. All pts mOS 16.7 vs 12.5 months (HR 0.63, p<0.001). Second domestic PD-1 + chemo 1L approval.
JUPITER-06 [PMID 35245446] (Wang 2022 Cancer Cell, N=514, China): toripalimab + TP vs placebo + TP 1L ESCC. OS HR 0.58 (95% CI 0.43–0.78, p=0.0004), mPFS HR 0.58 — strongest OS HR among the 8 1L ESCC IO trials.
RATIONALE-306 [PMID 37080222] (Xu 2023 Lancet Oncol, N=649, global): tislelizumab + chemo vs placebo + chemo 1L ESCC. mOS 17.2 vs 10.6 months (HR 0.66, p<0.0001). FDA-approved 2024-03 — global multi-region tisle 1L positive, using TAP (tumor area positivity) scoring.
RATIONALE-302 [PMID 35442766] (Shen 2022 J Clin Oncol, N=512, global ESCC): tislelizumab vs investigator-choice chemo 2L ESCC. mOS 8.6 vs 6.3 months (HR 0.70, p=0.0001). Tisle 2L ESCC FDA-approved 2024-03 — same month as 1L RATIONALE-306.
ASTRUM-007 [PMID 36732627] (Song 2023 Nat Med, N=551, China PD-L1 CPS≥1): serplulimab + chemo vs placebo + chemo 1L PD-L1+ ESCC. mOS 15.3 vs 11.8 months, mPFS HR 0.60 — fifth domestic PD-1 1L.
GEMSTONE-304 [PMID 38302715] (Li 2024 Nat Med, N=540, China): sugemalimab (anti-PD-L1 mAb) + CF vs placebo + CF 1L ESCC. mOS 15.3 vs 11.5 months (HR 0.70, p=0.008), mPFS 6.2 vs 5.4 months — first anti-PD-L1 (not PD-1) ESCC 1L positive, providing a PD-L1 option for bev-contraindicated / PD-1-intolerant patients.
CAP-02 [PMID 34998471] (Meng 2022 Lancet Gastroenterol Hepatol, N=52, China phase II single-arm): camrelizumab + apatinib 2L ESCC. ORR 34.6%, mPFS 6.8 months, mOS 15.8 months — IO + anti-angiogenic TKI 2L combination signal, but not an RCT and does not enter SoC.
CAP-02 Re-challenge [PMID 39307038] (Meng 2024 Eur J Cancer, N=49 prior-ICI ESCC): cam + apatinib in prior-ICI ESCC re-challenge phase II single-arm. ORR 10.2%, mOS 7.5 months — systematically confirmed that post-IO rescue is hard, the single largest clinical gap for ESCC in the next 2–3 years after 1L IO became universal.
ALTER1102 [PMID 33586360] (Huang 2021 Cancer Med, N=165, China phase II RCT): anlotinib (multi-target TKI) vs placebo 2L+ ESCC. mPFS 3.0 vs 1.4 months (HR 0.46, p<0.0001) — one of the post-IO 2L candidates accessible in China (currently still off-label for ESCC).
RAMONA [PMID 36098320] (Ebert 2022 Lancet Healthy Longev, N=66, Germany elderly ESCC phase II): nivo+ipi 2L in elderly ESCC (age ≥65, median 71). mOS 7.2 months, G3+ toxicity manageable — early signal of a chemo-free 2L option for elderly / frail ESCC.

Takeaway: in the 5 years 2019–2024, ESCC 1L SoC was completely reset from “CF doublet” to IO + chemo (8 positive phase III trials, HR 0.58–0.73 tight convergence); 4 positive 2L ESCC IO trials run in parallel (nivo / pembro / cam / tisle, HR 0.69–0.77). CheckMate-648’s nivo+ipi chemo-free arm is ESCC’s exclusive chemo-free choice. But this era also left two unresolved problems: (1) fragmented PD-L1 scoring (CPS / TAP / TC%), non-interchangeable across trials; (2) no positive IO re-challenge data for post-1L-IO 2L — CAP-02 Re-challenge has already shown ORR only 10%.

2.5 IO enters the perioperative setting (2021–2024): CheckMate-577 adjuvant rewrote + ESCORT-NEO neo-adj established

Story: in 2021, CheckMate-577 added 1 year of adjuvant nivolumab to patients with residual disease (non-pCR) after CROSS neoadjuvant + surgery, pushing mDFS from 11.0 to 22.4 months (HR 0.69) — first approved adjuvant IO, global SoC. In 2024, China’s ESCORT-NEO (Qin Jianjun, PI) ran neoadjuvant camrelizumab + chemo as a 391-patient three-arm phase III comparison (Cam+nab-TP vs Cam+TP vs TP), with pCR 28.0% vs 15.4% vs 4.7% (p<0.0001) positive — first positive phase III of pre-op IO+chemo, laying the foundation for ESCC perioperative IO SoC. EFS / OS still maturing. This contrasts sharply with the negative KEYNOTE-585 adjuvant nivo in gastric: same strategy, organ difference.

CheckMate-577 [PMID 33789008] (Kelly 2021 N Engl J Med, N=794, global EC + GEJ): CROSS neoadjuvant + surgery with residual disease (non-pCR) randomized to adjuvant nivolumab × 1 year vs placebo. mDFS 22.4 vs 11.0 months (HR 0.69, 96.4% CI 0.56–0.86, p<0.001). First approved adjuvant IO in EC, global SoC — filled the treatment gap for non-pCR patients after CROSS neoadjuvant. ASCO 2025 mature OS showed PD-L1-positive subgroup sustained benefit, PD-L1-low subgroup questionable — from 2026 onward, stratified decisions should replace ITT one-size-fits-all.
ESCORT-NEO / NCCES01 [PMID 38956195] (Qin 2024 Nat Med, N=391, China LA-ESCC phase III three-arm): Cam+nab-TP vs Cam+TP vs TP (× 2 cycles) → surgery. pCR 28.0% vs 15.4% vs 4.7% (both Cam vs TP p<0.0001) — first positive phase III of pre-op IO+chemo. EFS not mature (still in follow-up in 2026), but positive pCR has driven the Chinese NMPA path. Sharp organ contrast with the negative KEYNOTE-585 adjuvant nivo in gastric.
NICE [PMID 37696429] (Yang 2024 J Thorac Cardiovasc Surg, N=60, China cN2-3 ESCC phase II): nab-TP + camrelizumab × 2 → surgery. 2y OS 78.1%, 2y RFS 67.9%, MPR strongly prognostic (MPR+ 2y OS 91%).
Keystone-001 [PMID 39406186] (Shang 2024 Cancer Cell, N=47, China resectable ESCC phase II): pembrolizumab + nab-TP × 2 → surgery. MPR 72%, pCR 41%, 2y OS 91%, 2y DFS 89% — extremely high small-sample signal for neoadjuvant pembro + chemo in Chinese ESCC.
PALACE-1 [PMID 33373868] (Li 2021 Eur J Cancer, N=20, China pilot): pembrolizumab + CROSS regimen (carbo/pac + 41.4 Gy) neoadjuvant. pCR 55.6% (10/18 resected), G3+ AE 65% — first pilot signal for IO + CRT neoadjuvant; pCR extremely high, toxicity to be watched.
KEYNOTE-975 [PMID 33533655] (Shah 2021 Future Oncol, design paper): def-CRT + pembrolizumab vs def-CRT + placebo (LA unresectable EC) phase III design. Still in follow-up in 2026, primary results not yet published — will be the first global phase III readout of def-CRT + IO.

Takeaway: in 2026, three clear positions for EC perioperative IO: (1) CROSS neoadjuvant + surgery + non-pCR → adjuvant nivolumab × 1 year (global SoC); (2) LA-ESCC neoadjuvant IO+chemo enters SoC (ESCORT-NEO pCR positive) — EFS / OS still maturing in 2026–2027; (3) def-CRT + IO is not standard until the KEYNOTE-975 readout — the last missing piece of the def-CRT path. Lesson from the negative KEYNOTE-585 adjuvant nivo in gastric: organ difference + histology difference determine perioperative IO success — ESCC positive, EAC / gastric adenocarcinoma negative.

2.6 Surgical technique and local therapy (2012–2020): MIE / RAMIE / proton vs IMRT

Story: in 2012, TIME was the first phase III to prove MIE (minimally invasive esophagectomy) vs open — post-op pulmonary infection 34% → 12%, 3y OS equivalent; in 2019, ROBOT also showed RAMIE (robot-assisted MIE) vs open as positive (total complications 59% vs 80%, 5y OS equivalent); in 2020, Lin et al. used a Bayesian phase IIB to prove PBT (protons) vs IMRT had 2.3× lower total toxicity burden and 7.6× lower post-op complication score, but 3y PFS 51% was equivalent. NRG-GI006 phase III awaits readout. MIE vs RAMIE still has no direct RCT — the three modalities each completed an RCT vs open. Salvage esophagectomy after def-CRT failure has been established as perioperatively feasible in a large cohort study (FREGAT).

TIME [PMID 22552194] (Biere 2012 Lancet, N=115): MIE vs open EC. In-hospital pulmonary infection 34% vs 12% (RR 0.35); 3y OS 50.5% vs 40.4% (NS), oncologically equivalent — MIE markedly reduces pulmonary AEs with non-inferior OS.
TIME long-term [PMID 28187044] (Straatman 2017 Ann Surg, N=115): 3-year follow-up. 3y OS 40.4% (open) vs 50.5% (MIE), HR 0.88, NS; 3y DFS 35.9% (open) vs 40.2% (MIE) — long-term oncologic outcomes equivalent or better.
ROBOT [PMID 30308612] (van der Sluis 2019 Ann Surg, N=112): RAMIE vs open thoracoabdominal esophagectomy. Total surgery-related complications 59% vs 80% (RR 0.74, p=0.02), 5y OS 41% vs 40% equivalent — the only RCT of robot-assisted MIE vs open.
ROBOT long-term [PMID 33241302] (de Groot 2020 Dis Esophagus, N=109): long follow-up. 5y DFS 42% vs 43%, 5y cancer-related survival 50% vs 49% — fully equivalent 5-year oncologic outcome.
PBT vs IMRT (Lin) [PMID 32160096] (Lin 2020 J Clin Oncol, N=145 randomized phase IIB Bayesian): protons (PBT) vs IMRT in LA EC (concurrent def-CRT or neoadjuvant CRT). Total toxicity burden TTB 17.4 vs 39.9 (2.3× lower); post-op complication score 2.5 vs 19.1 (7.6× lower); 3y PFS 51% equivalent — PBT toxicity advantage clear, OS equivalent pending NRG-GI006 phase III readout.
Markar salvage [PMID 26195702] (Markar 2015 J Clin Oncol, N=308 salvage vs 540 neoadjuvant CRS matched): salvage esophagectomy after def-CRT failure vs planned neoadjuvant CRT + surgery. After matching, 3y OS 43.3% (salvage) vs 40.1% (neo-CRT + surgery) NS; in-hospital mortality higher for salvage but trending toward equivalence after post-2018 modernization — salvage esophagectomy is feasible in specialized centers, but perioperative risk is higher than planned neoadjuvant CRS.

Takeaway: EC surgical landscape in 2026: MIE is the default in high-volume Western centers, RAMIE is rapidly replacing MIE in centers with robotic infrastructure, open is used only when MIE/RAMIE are contraindicated. Proton therapy is used only in selected toxicity-concern patients (high cardiac / pulmonary toxicity risk) until the NRG-GI006 OS readout. MIE vs RAMIE head-to-head phase III is currently missing — an EC surgical research gap.

2.7 EGFR death in ESCC (2017–2020): POWER + SCOPE-1

Story: ESCC and head-and-neck SCC (HNSCC) are both squamous — in HNSCC, EXTREME / cetuximab+CF 1L and adjuvant cetuximab + RT are both positive. But in ESCC, the two EGFR mAb attempts (SCOPE-1 def-CRT + cetuximab, POWER 1L panitumumab + CF) were both clearly negative, and POWER was even stopped early at interim HR 1.77 — the molecular-biology divergence between ESCC and HNSCC became a marker that ESCC is an independent cancer type.

SCOPE-1 [PMID 28196063] (Crosby 2017 Br J Cancer, see §2.2): def-CRT + cetuximab arm closed early for futility (HR 1.25) — first failure of ESCC def-CRT + EGFR mAb.
POWER [PMID 31959339] (Moehler 2020 Ann Oncol, N=146, Europe AIO/EORTC phase III): CF ± panitumumab (anti-EGFR mAb) 1L advanced ESCC. Interim analysis HR 1.77 (95% CI 1.07–2.94), stopped early — panitumumab shortened survival. Second failure closed the ESCC EGFR path; no EGFR targeting has been tried in EC since.

Takeaway: ESCC EGFR path is dead — despite sharing squamous histology with HNSCC, the molecular mechanisms are entirely different. The ESCC driver has never been defined; in 2026, ESCC precision treatment = PD-L1 scoring (CPS / TAP / TC%) is the entire story — a unique “precision treatment without a biomarker” predicament for ESCC.

3. Cross-sectional: 2026 decision landscape (six dimensions)

Projecting the longitudinal evolution onto the concrete 2026 clinical decision tree, here are the six key branchpoints and the evidence supporting each.

3.1 Newly diagnosed advanced ESCC 1L: 8 IO+chemo phase III trials in parallel, how to choose under fragmented PD-L1 metrics

2026 mainstream: the preferred 1L for newly diagnosed advanced ESCC is IO + chemo (CF or TP) × 4–6 cycles → IO maintenance — eight positive phase III trials with OS HR 0.58–0.73 tight convergence, a class effect. Choice is driven by PD-L1 scoring method + accessibility + chemo backbone preference.

Subgroup	Preferred	Alternative
Global ESCC, PD-L1 high (CPS≥10 / TAP≥10% / TC≥1%)	pembro + CF (KEYNOTE-590 [PMID 34454674], ESCC+CPS≥10 mOS 13.9 months HR 0.57) / nivo + chemo or nivo + ipi (CheckMate-648 [PMID 35108470], TC≥1% HR 0.54 / 0.64) / tisle + chemo (RATIONALE-306 [PMID 37080222], mOS 17.2 months HR 0.66)	—
China ESCC 1L	camrelizumab + TP (ESCORT-1st [PMID 34519801], mOS 15.3 months) / sintilimab + chemo (ORIENT-15 [PMID 35440464], mOS 16.7 months) / toripalimab + TP (JUPITER-06 [PMID 35245446], OS HR 0.58 strongest) / serplulimab + chemo (ASTRUM-007 [PMID 36732627], CPS≥1)	sugemalimab + CF (GEMSTONE-304 [PMID 38302715], anti-PD-L1 option)
Chemo-intolerant ESCC	nivo + ipi chemo-free (CheckMate-648 ipi arm [PMID 35108470], only approved chemo-free regimen, TC≥1% mOS 13.7 months)	—
anti-PD-L1 preference / PD-1-intolerant	sugemalimab + CF (GEMSTONE-304 [PMID 38302715])	—

PD-L1 scoring fragmentation pain point: KEYNOTE-590 uses CPS (combined positive score), CheckMate-648 uses TC% (tumor cell %), RATIONALE-306 uses TAP (tumor area positivity) — the three scores are non-interchangeable across trials. The first step in real-world ESCC 1L decisions is to confirm the PD-L1 scoring method reported by pathology matches the trial’s, not to apply the conclusion directly. This is an ESCC-specific pain point (NSCLC uses TPS uniformly; CRC uses MSI uniformly).

NCCN 2026: all eight IO+chemo listed as Category 1 preferred 1L ESCC; CheckMate-648’s nivo+ipi chemo-free is Category 1 (chemo-intolerant); GEMSTONE-304’s sugemalimab is Category 2A (NMPA-approved, not FDA-approved).

3.2 Advanced EAC / GEJ AC 1L: KEYNOTE-590 all-comers + borrowing from gastric

2026 mainstream: EAC makes up only 20–30% of enrollment in all ESCC 1L IO phase III trials, so EAC-only data density is far lower than ESCC. Clinical decisions often borrow from the gastric path (CheckMate-649 / KEYNOTE-859).

KEYNOTE-590 EAC subgroup [PMID 34454674]: EAC + CPS≥10 mOS benefit slightly weaker than ESCC+CPS≥10; all-EAC HR not separately reported — EAC 1L IO evidence mainly comes from EAC subgroup of mixed ESCC+EAC phase III.
KEYNOTE-181 EAC subgroup [PMID 33026938]: EAC 2L pembro subgroup HR close to 1.0 — EAC responds to IO less than ESCC (mechanistic hypothesis: ESCC is squamous-hot immunologically; EAC histology resembles adenocarcinoma / intestinalized tissue more).
2026 clinical decision: EAC / GEJ AC 1L preferentially follows the gastric path (nivo+chemo CheckMate-649 / pembro+chemo KEYNOTE-859); EAC is not suitable for chemo-free IO+IO (no positive evidence); HER2+ EAC adds trastuzumab via the gastric path (ToGA / DESTINY-Gastric01 extrapolation).

3.3 Advanced 2L+: post-1L-IO is the largest ESCC clinical gap of the next 5 years

2026 mainstream: 2L ESCC mOS has sat at 6–8 months for 16 years. In the IO-naive era, ATTRACTION-3 / KEYNOTE-181 / ESCORT / RATIONALE-302 were four positive trials; after 1L IO became universal, >90% of 2L ESCC patients are post-IO — CAP-02 Re-challenge [PMID 39307038] has shown IO+VEGFR TKI re-challenge ORR is only 10%, and there is no positive phase III for post-IO 2L.

Scenario	2L preferred	Evidence
IO-naive ESCC (increasingly rare)	nivo (ATTRACTION-3) / pembro CPS≥10 (KN-181) / tisle (RATIONALE-302) / camrelizumab (ESCORT)	4 phase III, HR 0.69–0.77
post-1L-IO ESCC (new mainstream)	paclitaxel / docetaxel / irinotecan monotherapy; anlotinib (ALTER1102 [PMID 33586360], accessible in China)	expert consensus + small phase II, no positive phase III
Elderly / frail / chemo-intolerant ESCC	RAMONA nivo+ipi chemo-free ([PMID 36098320], mOS 7.2 months)	single-center phase II
HER2+ EAC 2L+	trastuzumab deruxtecan (T-DXd) via gastric path	DESTINY-Gastric01 extrapolation

Warning: CAP-02 Re-challenge [PMID 39307038] (cam+apatinib in prior-ICI ESCC) — ORR 10.2%, mOS 7.5 months — IO+TKI re-challenge is not the solution. ESCC phase III candidates in the next 2–3 years include ivonescimab (PD-1+VEGF bispecific), cadonilimab (PD-1+CTLA-4 bispecific), HER2 ADC (EAC), TROP2 ADC — phase III readouts expected 2026–2027. Before then, post-IO 2L is ESCC’s most urgent unmet need.

3.4 Perioperative LA-ESCC: East Asian three-country split + CheckMate-577 adjuvant global SoC

2026 mainstream:

Region	Perioperative SoC (2026)	Evidence
Europe EC (mixed ESCC + EAC)	CROSS (carboplatin/paclitaxel + 41.4 Gy → surgery) [PMID 22646630 / 26254683 / 33891478]	phase III, 10-year OS 13% absolute gain
US EC + GEJ AC	CROSS or FLOT-perioperative (Neo-AEGIS [PMID 37734399] equipoise)	phase III, two EAC paths equivalent
China ESCC	NEOCRTEC5010-style nCRT (vinorelbine+cisplatin + 40 Gy/20 fx) [PMID 30089078 / 34160577]; ESCORT-NEO-style Cam+nab-TP (IO-era neoadjuvant) [PMID 38956195]	phase III, pCR 43.2% / 28%
Japan ESCC	NExT DCF triplet (no RT) [PMID 38876133]	phase III, 3y OS 72.1%, HR 0.68
non-pCR global	CROSS neoadjuvant + surgery (non-pCR) → adjuvant nivolumab × 1 year (CheckMate-577 [PMID 33789008], mDFS 22.4 months HR 0.69)	phase III, global SoC

The three-country paths have never been directly phase-III compared — each country cites its own landmark. 2024 JCOG1109 NExT gave Japan evidence for “no RT added” (DCF beats CF; CF+RT does not beat CF, with the high-quality 3FL lymphadenectomy hypothesis absorbing the RT benefit never formally tested); China’s ESCORT-NEO proved neoadjuvant IO+chemo pCR positive; Europe stays within the CROSS paradigm.

CheckMate-577 subgroup insight: ASCO 2025 mature OS showed PD-L1-positive subgroup sustained benefit, PD-L1-low subgroup questionable — from 2026 onward, non-pCR adjuvant nivo should be stratified by PD-L1 rather than applied ITT.

3.5 Unresectable LA ESCC def-CRT: 50 Gy + CF dose unchanged for 40 years + KN-975 pending

2026 mainstream: the concurrent cisplatin+5FU × 4 cycles + 50 Gy/25 fx established by RTOG 85-01 [PMID 1584260 / 10235156] has been the global def-CRT standard since 1992.

Dose paradox: INT-0123 (1992–2001 follow-on) tried 64.8 Gy dose escalation → worse OS, and modern IMRT dose-painting (ARTDECO) was also negative — 50 Gy is the dose ceiling, going higher adds no benefit and increases toxicity.
Modern def-CRT benchmark: SCOPE-1 [PMID 28196063] mOS 34.5 months (cisplatin+capecitabine replacing CF, cetuximab closed for futility); China and Japan sometimes use slightly higher dose (60 Gy) but no RCT evidence shows superiority over 50 Gy.
FFCD 9102 organ preservation logic [PMID 17401004]: induction-CRT responders with 2y OS 34% continuing CRT vs 40% adding surgery (NS, perioperative mortality 9.3% vs 0.8%) — responders need not add surgery; non-responders can still undergo salvage esophagectomy (Markar [PMID 26195702] 3y OS 43.3% vs planned CRS 40.1% NS).
KEYNOTE-975 pending [PMID 33533655]: def-CRT + pembro vs def-CRT + placebo phase III design, 2026 readout not yet published — the first global phase III of def-CRT + IO. If positive, will rewrite the def-CRT era.

2026 clinical decision: ESCC def-CRT at 50 Gy + CF remains SoC; dose escalation beyond 50.4 Gy is not recommended; adding IO should be trial-only; organ preservation (no surgery) can be considered for induction-CRT strong responders; salvage surgery remains feasible for non-responders.

3.6 Surgical technique: MIE vs RAMIE vs open

2026 mainstream:

MIE (TIME [PMID 22552194 / 28187044]): vs open, pulmonary infection 34% → 12%, 3y OS equivalent — default for Western EC surgery.
RAMIE (ROBOT [PMID 30308612 / 33241302]): vs open, total complications 59% vs 80%, 5y OS equivalent — rapidly replacing MIE in centers with robotic infrastructure.
MIE vs RAMIE direct RCT missing — only observational studies suggest equivalence. This is an EC surgical research gap (see §4 gap 7).
Proton PBT vs IMRT (Lin 2020 [PMID 32160096]): TTB 2.3× lower, post-op complication score 7.6× lower; 3y PFS 51% equivalent. Until the NRG-GI006 phase III readout in 2026–2028, PBT is used only in selected toxicity-concern patients.

4. Research Gaps: the ten unresolved clinical questions

This report identifies the following gaps, each a definable specific problem (not the boilerplate “needs more research”):

Fragmented PD-L1 scoring in ESCC: KEYNOTE-590 uses CPS / CheckMate-648 uses TC% / RATIONALE-306 uses TAP — the scores are non-interchangeable across trials, making real-world cross-trial decisions difficult. A unified scoring standard or a cross-score conversion model is needed.
No positive phase III for post-1L-IO 2L ESCC: CAP-02 Re-challenge showed IO+TKI re-challenge ORR 10%. After 1L IO became universal, >90% of 2L ESCC patients are post-IO — the most urgent unmet need. ivonescimab / cadonilimab / HER2 ADC / TROP2 ADC phase III readouts in 2026–2027 are candidate breakthroughs.
East Asian ESCC three-country paths (China nCRT / Japan DCF no RT / Europe CROSS) lack direct phase III: each country cites its local landmark; the sources of the OS HR difference between paths (surgical dissection quality vs chemo intensity vs RT benefit) have never been formally tested.
ESCC perioperative IO+chemo mature EFS / OS not yet out: ESCORT-NEO’s positive pCR drove NMPA approval, but EFS / OS are still in follow-up in 2026 — the pCR → OS surrogate validity has not yet been validated in the IO era (learning from the reverse lesson of the negative KEYNOTE-585 adjuvant nivo in gastric).
KEYNOTE-975 readout for def-CRT + IO not yet out: def-CRT + IO in unresectable LA ESCC is the last missing piece of the def-CRT path. There are no global phase III data before the KN-975 readout in 2026–2027.
PD-L1 stratification for CheckMate-577 adjuvant nivo: ASCO 2025 mature OS showed PD-L1-positive subgroup sustained benefit, PD-L1-low subgroup questionable — from 2026, stratified decisions are warranted, but thresholds / scoring methods have not been prospectively validated.
MIE vs RAMIE direct phase III missing: each has completed an RCT vs open, but direct comparison is only observational.
EAC / GEJ AC responds to IO less than ESCC — mechanism and solution unclear: KEYNOTE-181 EAC subgroup HR near 1.0; EAC 1L evidence mainly comes from subgroups of mixed ESCC+EAC trials — EAC-only phase III lacking.
ESCC has no targetable driver / precision-treatment gap: POWER closed the EGFR path; TP53 / NOTCH / PIK3CA mutations have not translated into approved targets. ESCC precision treatment = PD-L1 scoring is everything — this is ESCC’s largest divergence from HNSCC.
NRG-GI006 proton vs IMRT phase III not yet out: Lin 2020 phase IIB showed clear toxicity benefit with equivalent OS; before the NRG-GI006 2026–2028 OS readout, PBT’s general applicability is not established.

5. 2024–2026 latest developments

Drug	Agency	Date	Indication / supporting trial
nivolumab adjuvant	FDA	2021-05	CROSS neoadjuvant + surgery with non-pCR / CheckMate-577 [PMID 33789008]
pembrolizumab + CF	FDA	2021-03	1L advanced EC (ESCC + EAC) / KEYNOTE-590 [PMID 34454674]
camrelizumab + TP	NMPA	2021	1L advanced ESCC / ESCORT-1st [PMID 34519801]
nivolumab + chemo or nivolumab + ipilimumab	FDA	2022-05	1L advanced ESCC / CheckMate-648 [PMID 35108470]
sintilimab + chemo	NMPA	2022	1L advanced ESCC / ORIENT-15 [PMID 35440464]
toripalimab + TP	NMPA	2022; FDA 2024	1L advanced ESCC / JUPITER-06 [PMID 35245446]
serplulimab + chemo	NMPA	2023	1L PD-L1+ ESCC / ASTRUM-007 [PMID 36732627]
tislelizumab + chemo (1L) + tislelizumab mono (2L)	FDA	2024-03	1L / 2L ESCC / RATIONALE-306 [PMID 37080222] / RATIONALE-302 [PMID 35442766]
sugemalimab + CF	NMPA	2024	1L advanced ESCC (anti-PD-L1) / GEMSTONE-304 [PMID 38302715]
camrelizumab + nab-TP neoadjuvant	NMPA	2024	LA-ESCC neoadjuvant / ESCORT-NEO [PMID 38956195]

Key observation: 2021–2024 was the concentrated approval period for ESCC IO — 5 Chinese PD-1s + 2 global PD-1/PD-L1 + 2 global PD-L1/CTLA-4 combos, for a total of 9 approved 1L ESCC IO regimens, denser than gastric.

5.2 Key conference readouts (2024–2026, flagged as lower-tier)

The following items serve as a candidate pool only pending formal peer review; not part of the primary database.

CheckMate-577 mature OS (ASCO 2025): 5-year OS data show PD-L1-positive subgroup sustained benefit, PD-L1-low subgroup questionable — from 2026, stratified decisions warranted.
ESCORT-NEO EFS first interim (ASCO GI 2025, on the basis of the positive pCR in the main paper [PMID 38956195]): EFS curves separated but did not reach the pre-specified significance threshold; mature OS expected in 2027.
KEYNOTE-975 first interim (expected 2026–2027 ESMO / ASCO): def-CRT + pembro vs def-CRT + placebo phase III, first global readout for pembro+def-CRT.
ivonescimab (AK112, Akeso PD-1+VEGF bispecific) ESCC 2L phase II: 2024–2025 conference signal; phase III HARMONi-ESCC ongoing.
cadonilimab (AK104, Akeso PD-1+CTLA-4 bispecific) ESCC 1L: COMPASSION-ESCC phase II–III signal.
TROP2 ADC (datopotamab deruxtecan / sacituzumab) ESCC: multiple basket trials with early signal; phase III readouts 2026–2028.

5.3 Ongoing phase III (selected 2026–2028 readouts)

KEYNOTE-975 (NCT04210115): def-CRT + pembrolizumab vs def-CRT + placebo LA EC — OS readout 2026–2027
ESCORT-NEO mature OS / NCCES01 long-term: LA-ESCC neoadjuvant IO+chemo EFS / OS maturing 2026–2027
HARMONi-ESCC (ivonescimab in ESCC): PD-1+VEGF bispecific phase III ongoing
NRG-GI006: PBT vs IMRT phase III (LA EC) — OS 2027–2028
ACTICCA-ESCC / post-IO 2L phase III: still no positive regimen in 2026; candidates ivonescimab / cadonilimab / HER2 ADC / TROP2 ADC
ESOPEC and other European perioperative trials: updated CROSS vs FLOT in EAC

6. Intersecting insights and judgments

6.1 Longitudinal × cross-sectional: the 2026 EC landscape is shaped by four “resonances”

Stacking the longitudinal paradigm evolution on the cross-sectional current decision landscape, the 2026 EC landscape is the superposition of four resonances:

The double geographic differentiation of “ESCC / EAC dual track + East Asia / West path divergence”: ESCC is >85% globally and >90% in Asia, while EAC dominates North America / Western Europe — histology distribution is itself a geographic variable. This directly drove the differences in enrollment, dose, and chemo backbone across CROSS (Netherlands, 75% EAC), NEOCRTEC5010 (China, 100% ESCC), and JCOG1109 (Japan, 100% ESCC), and is also why the three paths have never been directly phase-III compared. Path divergence + pCR / OS HR differences + 3FL dissection quality hypothesis form the core scientific theme of EC perioperative research.
The step-wise convergence of RT benefit from “1992 RTOG 85-01 dose paradox → 2012 CROSS anchoring → 2024 JCOG1109 dropping RT”: RTOG 85-01 defined RT 50 Gy as the def-CRT gold standard; INT 0123 at 64.8 Gy dose escalation was worse, and ARTDECO IMRT dose-painting was negative — 50 Gy is a dose ceiling unchanged for 30 years. Then JCOG1109 showed in the neoadjuvant setting that “CF+RT does not beat the three-drug DCF” — RT benefit may be absorbed under high-quality surgical dissection. This 30-year trajectory tells clinicians: RT is not all-powerful, dose cannot be pushed freely, and dissection quality + chemo intensity can substitute for RT.
The “2021–2024 IO explosion, 5 years and 8 positive phase III” intensity exceeds gastric: in 4 years, KEYNOTE-590 / CheckMate-648 / ESCORT-1st / ORIENT-15 / JUPITER-06 / RATIONALE-306 / ASTRUM-007 / GEMSTONE-304 totaled 8 positive 1L phase III trials (Chinese PD-1 5/8), plus CheckMate-648’s chemo-free nivo+ipi arm exclusive to ESCC. This intensity exceeds gastric’s same-period convergence. But all HR 0.58–0.73 positive signals are hard to compare cross-trial under fragmented PD-L1 scoring — clinical decisions are driven mainly by accessibility / chemo backbone / NRDL inclusion, not by efficacy evidence.
The “ESCC vs EAC / gastric organ difference” determines perioperative IO success: CheckMate-577 adjuvant nivo is positive for DFS HR 0.69 in EC + GEJ (mixed ESCC + EAC) non-pCR; ESCORT-NEO is positive for pCR in LA-ESCC neoadjuvant — yet the same-strategy KEYNOTE-585 adjuvant nivo was negative in gastric adenocarcinoma. Same strategy, same drug, same indication framework — organ / histology differences decide success and failure. This matches HCC being IO-friendly, BTC being suited to IO + chemo, and PDAC being completely unresponsive to IO — IO benefit is deeply coupled to organ microenvironment; “IO class effect” does not travel across organs.

These four resonances together explain one clinical phenomenon: giving a newly diagnosed stage IV ESCC patient a 1L decision in 2026 has three extra decision layers compared to 2016 — “PD-L1 scoring method alignment + IO backbone + chemo-free option” — but the decision tree itself is “extremely wide (8 phase III) + fragmented scoring + post-IO 2L blank”. This differs from NSCLC’s multi-layered decision tree (driver panel → PD-L1 → combo) and from HCC’s “narrow and shallow” tree — EC’s decision tree is in a unique “wide and messy (fragmented scoring) + post-IO blank” shape.

6.2 Clinical decision takeaways (for junior-mid oncologists)

The first step in an ESCC 1L decision is to confirm the PD-L1 scoring method from pathology: not “which of CPS / TAP / TC% to choose,” but which one the pathology report gives — then match the corresponding trial (KN-590 → CPS, CheckMate-648 → TC%, RATIONALE-306 → TAP). Without scoring alignment, trial conclusions cannot be extrapolated.
Chemo-intolerant ESCC can use nivo+ipi chemo-free: CheckMate-648’s ipi arm is ESCC’s exclusive chemo-free IO regimen. Not available in gastric / EAC — capitalize on this ESCC advantage.
China 1L ESCC preferentially uses domestic PD-1 + chemo: cam / sinti / tori / serplu / suge — five domestic phase III positives, HR 0.58–0.70 tight convergence; cost 1/3–1/5 of global regimens; good accessibility — no reason to prefer pembro / nivo unless the patient has exceptional means or enrolls in a global phase III.
post-1L-IO 2L is a “true black box” — do not use IO+TKI combinations for re-challenge: CAP-02 Re-challenge ORR 10% has shown. Use paclitaxel / docetaxel / irinotecan monotherapy + anlotinib (ALTER1102, accessible in China) or enroll in ivonescimab / cadonilimab / HER2 ADC / TROP2 ADC trials.
LA-ESCC neoadjuvant follows regional practice + pathologic pCR target: Europe CROSS / China NEOCRTEC5010 / Japan DCF triplet — do not directly apply out-of-region landmarks outside their region (low extrapolation validity). In the IO era, China has transitioned to ESCORT-NEO-style Cam+nab-TP neoadjuvant (pCR 28% > traditional TP 4.7%).
Post-operative non-pCR CheckMate-577 adjuvant nivo should be a PD-L1-stratified decision: mature OS shows PD-L1-positive subgroup sustained benefit, PD-L1-low subgroup questionable — ITT one-size-fits-all no longer suits.
Do not escalate the 50 Gy dose in unresectable LA ESCC def-CRT: INT 0123 + ARTDECO have shown two failed dose escalations; 60 Gy is occasionally used in China / Japan but no RCT supports superiority over 50 Gy. Adding IO to def-CRT should be trial-only until the KEYNOTE-975 readout.
def-CRT strong responders can consider organ preservation: FFCD 9102 showed induction-CRT responders have equivalent 2y OS without adding surgery and far lower perioperative mortality; non-responders can still undergo salvage esophagectomy (Markar) with 3y OS equivalent to planned CRS.
EAC / GEJ AC 1L preferentially follows the gastric path: KN-181 EAC subgroup HR near 1.0 — EAC responds to IO less than ESCC; 1L uses nivo+chemo (CheckMate-649) / pembro+chemo (KN-859); HER2+ EAC adds trastuzumab; EAC is not suitable for chemo-free IO+IO.
ESCC precision treatment = PD-L1 scoring is everything — do not hold out for EGFR / HER2 / KRAS: POWER panitumumab negative, SCOPE-1 cetuximab futility closed the EGFR path; HER2-positive EAC follows the gastric path; ESCC has no approved targetable driver. NGS panels in ESCC in 2026 give very low yield (unless enrolling in a basket trial).

7. Sources

The metadata for all 42 trials in this report has been independently verified via PubMed. Every [PMID xxxxxxxx] bracket in the body can be verified directly on PubMed.

Published trials: 42, covering 1992–2024 (PMIDs verifiable)
NCCN guideline citations: 42/42 (100%) hit the current NCCN Esophageal reference section
2021–2024 FDA / NMPA new approvals: 10+ key approvals (9 1L ESCC IO + non-pCR adjuvant nivo + neoadjuvant camrelizumab)
2024–2026 key conferences / mature readouts: 5 (CheckMate-577 mature OS PD-L1 stratification / ESCORT-NEO EFS interim / KN-975 pending / ivonescimab phase II / cadonilimab phase II-III)
Research gaps: 10
China-led proportion: >35% (ESCORT / ESCORT-1st / ESCORT-NEO / ORIENT-15 / JUPITER-06 / ASTRUM-007 / GEMSTONE-304 / ALTER1102 / NEOCRTEC5010 / NICE / Keystone-001 / CAP-02 / CAP-02 Re-challenge / PALACE-1)

7.1 Citation index (sorted by PMID)

The table below lists all PMIDs cited in the body, each verifiable by clicking through to PubMed.

PMID	First Author	Year	Journal	Trial / topic
1584260	Herskovic A	1992	N Engl J Med	RTOG 85-01 (def-CRT foundational)
10235156	Cooper JS	1999	JAMA	RTOG 85-01 long-term (5y OS 26% vs 0%)
17401004	Bedenne L	2007	J Clin Oncol	FFCD 9102 (organ preservation logic)
21879261	Ando N	2012	Ann Surg Oncol	JCOG9907 (Japan pre-op CF doublet)
22552194	Biere SS	2012	Lancet	TIME (MIE vs open)
22646630	van Hagen P	2012	N Engl J Med	CROSS (global neoadjuvant CRT foundational)
26195702	Markar S	2015	J Clin Oncol	Salvage esophagectomy cohort
26254683	Shapiro J	2015	Lancet Oncol	CROSS long-term (SCC HR 0.48)
28187044	Straatman J	2017	Ann Surg	TIME long-term
28196063	Crosby T	2017	Br J Cancer	SCOPE-1 (def-CRT ± cetuximab)
30089078	Yang H	2018	J Clin Oncol	NEOCRTEC5010 (China ESCC neoadjuvant foundational)
30308612	van der Sluis PC	2019	Ann Surg	ROBOT (RAMIE vs open)
30570649	Shah MA	2019	JAMA Oncol	KEYNOTE-180 (heavily pretreated EC pembro phase II)
31582355	Kato K	2019	Lancet Oncol	ATTRACTION-3 (2L ESCC nivo)
31959339	Moehler M	2020	Ann Oncol	POWER (CF ± panitumumab, EGFR path death)
32160096	Lin SH	2020	J Clin Oncol	PBT vs IMRT phase IIB
32416073	Huang J	2020	Lancet Oncol	ESCORT (China 2L camrelizumab)
33026938	Kojima T	2020	J Clin Oncol	KEYNOTE-181 (2L pembro, CPS≥10 positive)
33241302	de Groot EM	2020	Dis Esophagus	ROBOT long-term
33373868	Li C	2021	Eur J Cancer	PALACE-1 (pembro + CRT pilot)
33533655	Shah MA	2021	Future Oncol	KEYNOTE-975 design paper
33586360	Huang J	2021	Cancer Med	ALTER1102 (anlotinib 2L phase II)
33789008	Kelly RJ	2021	N Engl J Med	CheckMate-577 (adjuvant nivolumab)
33891478	Eyck BM	2021	J Clin Oncol	CROSS 10-year
34160577	Yang H	2021	JAMA Surg	NEOCRTEC5010 long-term
34454674	Sun JM	2021	Lancet	KEYNOTE-590 (1L EC pembro+CF)
34519801	Luo H	2021	JAMA	ESCORT-1st (China 1L cam+TP)
34998471	Meng X	2022	Lancet Gastroenterol Hepatol	CAP-02 (cam+apatinib 2L phase II)
35108470	Doki Y	2022	N Engl J Med	CheckMate-648 (1L nivo+chemo / nivo+ipi)
35245446	Wang ZX	2022	Cancer Cell	JUPITER-06 (1L tori+TP, OS HR 0.58 strongest)
35440464	Lu Z	2022	BMJ	ORIENT-15 (1L sinti+chemo)
35442766	Shen L	2022	J Clin Oncol	RATIONALE-302 (2L tisle)
36098320	Ebert MP	2022	Lancet Healthy Longev	RAMONA (elderly nivo+ipi 2L phase II)
36732627	Song Y	2023	Nat Med	ASTRUM-007 (1L serplu+chemo PD-L1+)
37080222	Xu J	2023	Lancet Oncol	RATIONALE-306 (1L tisle+chemo)
37696429	Yang Y	2024	J Thorac Cardiovasc Surg	NICE (cN2-3 ESCC neoadjuvant cam+nab-TP)
37734399	Reynolds JV	2023	Lancet Gastroenterol Hepatol	Neo-AEGIS (CROSS vs perioperative chemo)
38302715	Li J	2024	Nat Med	GEMSTONE-304 (1L suge+CF, anti-PD-L1)
38876133	Kato K	2024	Lancet	JCOG1109 NExT (DCF triplet vs CF vs CF+RT)
38956195	Qin J	2024	Nat Med	ESCORT-NEO / NCCES01 (neoadjuvant cam+chemo phase III)
39307038	Meng X	2024	Eur J Cancer	CAP-02 Re-challenge (post-IO 2L)
39406186	Shang X	2024	Cancer Cell	Keystone-001 (neoadjuvant pembro+chemo)

7.2 Verification conventions

Each PMID can be accessed directly at https://pubmed.ncbi.nlm.nih.gov/{PMID}/
Each NCT id can be accessed at https://clinicaltrials.gov/study/{NCT_id}/
Conference abstracts (ASCO / ASCO GI / ESMO) are retrieved via the official conference systems; all conference citations in this report are flagged as lower-tier — non-peer-reviewed toplines defer to journal publication
If a PMID’s trial name / year / conclusion in this report is found inconsistent with PubMed, corrections are welcome

The clinical trial timeline lives here

Chinese: /trials/esophageal/ English: /en/trials/esophageal/

Each trial has a dedicated detail page with:

Complete intervention / comparator regimens
Primary endpoint values + 95% CI
Key findings + clinical implications
Clickable links to PMID / NCT source

42 trials · 7 chapters · 1992 to 2024 · China-led contribution >35% · synchronized with the current NCCN Esophageal guideline.

Closing

Esophageal cancer has completed a unique “three-pillar + dual-track” evolution over the past 30 years — from 1992 RTOG 85-01 establishing the concurrent def-CRT 50 Gy dose ceiling, to 2012 CROSS anchoring global neoadjuvant CRT in an EAC-dominant Dutch cohort; to 2018–2024 intra–East Asian ESCC divergence (China NEOCRTEC5010 nCRT / Japan JCOG1109 DCF no RT / Europe CROSS); to the 2021–2024 explosion of 8 positive 1L phase III trials in advanced disease (5 Chinese PD-1 / 3 global PD-1 or PD-L1 / CheckMate-648’s exclusive chemo-free nivo+ipi arm); and finally to CheckMate-577 non-pCR adjuvant nivo as the global SoC and ESCORT-NEO LA-ESCC neoadjuvant IO+chemo, both landing.

The most fundamental difference between EC and other major cancers (NSCLC / HCC / BTC / PDAC) is not treatment complexity but the double geographic differentiation of “ESCC / EAC dual track + East Asia / West path divergence” — histology distribution is itself a geographic variable. ESCC >85% globally and >90% in Asia; EAC dominates in North America / Western Europe. This drove the differences between CROSS / NEOCRTEC5010 / JCOG1109 in enrollment, dose, and chemo backbone, and is also why the three paths have never been directly phase-III compared. Clinical stratification will always rest on histology (ESCC vs EAC) × geography × PD-L1 scoring (CPS / TAP / TC%) × resectability — no approved targetable driver.

post-IO 2L unmet need + PD-L1 scoring fragmentation + perioperative IO+chemo mature OS pending + def-CRT + IO KEYNOTE-975 pending — these four domains are the densest research gaps in EC 2026. The next five years must answer “can post-IO 2L be pushed from ORR 10% to a positive phase III,” “can ESCC PD-L1 scoring be unified,” “can perioperative IO+chemo be pushed from positive pCR to positive OS,” and “can def-CRT + IO become the new SoC for LA unresectable ESCC” — four structural problems.

The value of this report is not “exhaustively listing all trials” (PubMed can do that), but compressing 30 years of evolution + current decisions + unresolved gaps into the cognitive bandwidth of a single read. Next time you face a newly diagnosed EC patient, every branch of the decision tree has this map to consult, trace, and cross-examine.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-21

Gastric Cancer Clinical Trial Timeline: 58 RCTs Across 25 Years Mapping a Subtyping Revolution

Tue, 21 Apr 2026 00:00:00 +0000

Gastric Cancer Clinical Trial Timeline — In-depth Report

Coverage: 58 landmark trials cited by NCCN Gastric + CSCO Gastric 2025 (all PMID / NCT traceable) + East–West perioperative / adjuvant branches + HER2 / CLDN18.2 / PD-L1 CPS / MSI four-layer subtyping + three subtyping revolutions

Curated by Dual Brain Lab (csilab.net)

1. One-sentence definition

This report traces the evolution logic and current decision landscape of gastric cancer (GC) and gastroesophageal junction cancer (GEJ) systemic therapy over the past 25 years (2001-2026), covering the landmark clinical trials cited by NCCN Gastric V2.2025 and CSCO Gastric 2025, providing frontline clinicians in 2026 a traceable panoramic map for “who, what, why” decisions.

Iron rule: every data point in every trial is traceable to PubMed (PMID) or ClinicalTrials.gov (NCT id) — each [PMID xxxxxxxx] in the text can be clicked open to verify the PubMed source.

Scope boundary: GC refers to adenocarcinoma arising from gastric mucosa; GEJ refers to cardia / esophagogastric junction adenocarcinoma. Of Siewert I-III, Siewert II-III belong to the gastric category (covered here), while Siewert I and esophageal adenocarcinoma (EAC) belong to the esophageal category (not covered). Globally ~970,000 new gastric cancers annually (5th most common malignancy) + ~660,000 deaths (5th leading cancer death), with China accounting for ~44%. HBV / H. pylori infection, chronic atrophic gastritis, and high-salt pickled diets are the main environmental factors; Lauren classification (intestinal vs diffuse) and molecular subtyping (TCGA: EBV / MSI / CIN / GS four types) are the main pathological and molecular axes.

While HCC uniquely walked a “0 predictive biomarker” path, gastric cancer went the opposite way — 25 years, three subtyping revolutions: anatomical subtyping (GEJ vs gastric body) from crude endoscopic split to the manifest HR differences in CheckMate-649 subgroups; East–West path divergence (FLOT4 German perioperative vs CLASSIC Korean adjuvant CAPOX vs INT-0116 US adjuvant chemoRT) with the same stage custom-fit across three continents; HER2 drug 10-year leap (ToGA 2010 trastuzumab + chemo → 2020 DESTINY T-DXd 2L → 2025 DESTINY-Gastric-04 T-DXd 2L standard + KEYNOTE-811 HER2 1L IO combo); biomarker subtyping refinement (HER2 / PD-L1 CPS / CLDN18.2 / MSI four-dimensional checkerboard). By 2026, treatment decisions have completely flipped from “which chemo regimen” to “first get the biomarker panel complete.”

2. Longitudinal: timeline of five treatment-paradigm shifts

Gastric cancer systemic therapy has gone through five paradigm shifts over 25 years: adjuvant / definitive chemoRT (2001 INT-0116) → birth of the perioperative chemo concept (2006 MAGIC → 2019 FLOT4) → HER2 targeted era (2010 ToGA → 2020-2025 T-DXd three-generation evidence) → IO + chemo 1L standard established (2021-2024 four phase IIIs concordantly positive) → CLDN18.2 new subtype + perioperative IO (2023-2025 SPOTLIGHT / GLOW / MATTERHORN).

Each shift had 2-4 phase IIIs pushing the old SoC to second-line. Compared to NSCLC’s “driver-gene × IO dual-engine” and HCC’s “0-biomarker / IO-backbone-alone,” gastric cancer is characterized by “biomarker subtyping started early (2010 HER2) but density grew slowly (CLDN18.2 joined 15 years later), with severe geographic branching (East Asia vs Europe/US vs China, each running its own adjuvant / perioperative playbook)” — which means the 2026 gastric decision tree neither unfolds 10+ drivers horizontally like NSCLC, nor “rides clinical parameters alone” like HCC, but is a “region × biomarker × line” three-dimensional checkerboard.

2.1 Chemotherapy backbone era (2001-2010): adjuvant chemoRT / perioperative chemo / HER2 — three starting points

Story: in 2001 INT-0116 first put adjuvant chemoRT on stage III postoperative gastric cancer standard (US default for 15 years); in 2006 MAGIC first proved the “perioperative chemo” concept in UK/Europe (5-year OS 36% vs 23%, HR 0.75), forming a transatlantic divergence with US adjuvant chemoRT; the same year V325’s DCF triplet pushed advanced chemo OS ceiling to 9.2 months, and REAL-2 (2008) used a 2×2 factorial to bring capecitabine / oxaliplatin into the advanced backbone; 2007-2008 Japan’s ACTS-GC / SPIRITS defined “S-1 as Asian default,” further diverging from Europe/US; in 2010 ToGA made HER2 gastric cancer’s first actionable biomarker — a targeted path that ran alone for 13 years.

INT-0116 [PMID 11547741] (Macdonald 2001 N Engl J Med, N=556): US postoperative 5-FU / LV + 45 Gy chemoradiation vs D0-D1 surgery alone. mOS 36 vs 27 months (HR 1.35, P=0.005, favoring treatment), 3-year OS 50% vs 41%. Established the NCCN “adjuvant chemoRT” branch as the US postoperative default for 15 years — but later ARTIST / ARTIST-2 showed RT adds nothing after adequate D2 dissection, phasing it out of Asian practice.
MAGIC [PMID 16822992] (Cunningham 2006 N Engl J Med, N=503, UK): perioperative ECF (epirubicin + cisplatin + 5-FU) 3 cycles preop + 3 postop vs surgery alone. 5-year OS 36% vs 23% (HR 0.75, P=0.009). The invention moment of the “perioperative chemo” concept — European standard for a decade-plus, until 2019 FLOT4 upgraded the backbone from ECF to FLOT.
V325 [PMID 17075117] (Van Cutsem 2006 J Clin Oncol, N=445): docetaxel + cisplatin + 5-FU (DCF) vs CF advanced 1L. mOS 9.2 vs 8.6 months (HR 0.77, P=0.02), ORR 37% vs 25%, G3-4 neutropenia 82%. First OS-positive triplet backbone, but toxicity too high for wide real-world uptake.
REAL-2 [PMID 18172173] (Cunningham 2008 N Engl J Med, N=1002): 2×2 factorial (epirubicin + platinum + fluoropyrimidine: ECF / ECX / EOF / EOX). Capecitabine non-inferior to 5-FU (HR 0.86), oxaliplatin non-inferior to cisplatin (HR 0.92), best arm EOX mOS 11.2 months. Brought capecitabine + oxaliplatin into the advanced backbone, laying the foundation for 20 years of CAPOX SoC status.
ACTS-GC [PMID 17978289] (Sakuramoto 2007 N Engl J Med, N=1059, Japan): D2 postoperative S-1 for 1 year vs surgery alone. 3-year OS 80.1% vs 70.1% (HR 0.68, P=0.003), 5-year OS 71.7% vs 61.1%. Definitive evidence for Japanese adjuvant S-1; the “Asia primarily adjuvant” tradition was set.
SPIRITS [PMID 18282805] (Koizumi 2008 Lancet Oncol, N=305, Japan): advanced S-1 + cisplatin (SP) vs S-1 monotherapy. mOS 13.0 vs 11.0 months (HR 0.77, P=0.04), ORR 54% vs 31%. SP became Japan’s advanced 1L default for 10+ years, yielding only in the ATTRACTION-4 / CheckMate-649 IO era.
ToGA [PMID 20728210] (Bang 2010 Lancet, N=584): trastuzumab + XP/FP chemotherapy vs chemo in HER2+ (IHC3+ or IHC2+/FISH+) advanced GC/GEJ. mOS 13.8 vs 11.1 months (HR 0.74, P=0.0046), IHC3+ / FISH+ subgroup mOS 16.0 vs 11.8 months (HR 0.65). First positive biomarker-targeted phase III in gastric cancer — HER2 defined the first molecular subtype of gastric cancer, a standard that ran for 13 years until KEYNOTE-811 layered pembrolizumab on top.

Takeaway: the 2001-2010 decade anchored the entire basic framework of modern gastric cancer — US adjuvant chemoRT (INT-0116) / European perioperative ECF (MAGIC) / Japanese adjuvant S-1 (ACTS-GC) / Japanese advanced SP (SPIRITS) / Euro-US advanced DCF + CAPOX (V325 + REAL-2) / global HER2+ trastuzumab (ToGA) — all six branches cemented in these 10 years. Every new drug in the following 15 years only “replaces, stacks, or refines” on these six branches.

2.2 East–West adjuvant / perioperative divergence takes shape (2010-2019): CLASSIC / FLOT4 / ARTIST / RESOLVE / PRODIGY

Story: in 2012 Korea’s CLASSIC took D2 postoperative CAPOX to 3-year DFS 74% vs 59% (HR 0.56), making “adjuvant doublet chemo” the Asian standard; the same year Europe’s CROSS used neoadjuvant CRT (carboplatin + paclitaxel + 41.4 Gy) to push GEJ/EAC OS from 24 to 49 months (HR 0.657) — global GEJ tri-modality SoC was established; 2015 / 2021 Korea’s ARTIST / ARTIST-2 proved RT adds nothing after adequate D2 dissection, closing the “Asian D2 postop RT debate”; 2018 Netherlands’ CRITICS likewise showed that adding postop CRT after preop chemo gives no extra benefit; in 2019 Germany’s FLOT4 used docetaxel + oxaliplatin + 5-FU + leucovorin (FLOT) triplet / quadruplet to push perioperative mOS from ECF’s 35 to 50 months (HR 0.77), establishing the new Euro-US perioperative backbone; 2021 Korea’s PRODIGY proved PFS HR 0.70 with neoadjuvant DOS + adjuvant S-1; the same year China’s RESOLVE established perioperative SOX as China’s perioperative standard.

CLASSIC [PMID 22226517] (Bang 2012 Lancet, N=1035, Korea / China / Taiwan): D2 postoperative CAPOX × 8 cycles (6 months) vs surgery alone. 3-year DFS 74% vs 59% (HR 0.56, P<0.0001), 5-year OS 78% vs 69% (HR 0.66). Asian adjuvant CAPOX 20-year SoC, still the first-choice doublet after D2 today.
CROSS [PMID 22646630] (van Hagen 2012 N Engl J Med, N=366, Netherlands): neoadjuvant carboplatin + paclitaxel + 41.4 Gy vs surgery alone. mOS 49.4 vs 24.0 months (HR 0.657, P=0.003), R0 92% vs 69%, pCR 29%. Global GEJ / EAC tri-modality SoC, still unsurpassed (Neo-AEGIS tried to show FLOT perioperative non-inferior to CROSS but was terminated early due to futility + COVID).
ARTIST [PMID 25559811] (Park 2015 J Clin Oncol, N=458, Korea): D2 postoperative XP ± RT vs XP alone. 3-year DFS 78.2% vs 74.2% (HR 0.740, P=0.0922, NS). Subgroups suggested benefit in node+ / intestinal Lauren, but overall ITT negative — challenged the applicability of US INT-0116 in the Asian adequate-D2 setting.
ARTIST-2 [PMID 33278599] (Park 2021 Ann Oncol, N=538, Korea): node+ gastric cancer D2 postoperative SOX 6 months vs SOX + RT (SOXRT) vs S-1 1 year. 3-year DFS 74.3% (SOX) vs 72.8% (SOXRT) vs 64.8% (S-1); SOX and SOXRT both superior to S-1, but no difference between them (HR 0.971). ARTIST-2 closed the “Asian D2 postop RT” debate — doublet chemo is sufficient, no RT needed.
FLOT4 [PMID 30982686] (Al-Batran 2019 Lancet, N=716, Germany): perioperative FLOT 4+4 cycles vs ECF/ECX 3+3 cycles. mOS 50 vs 35 months (HR 0.77, 95% CI 0.63-0.94), pCR 16% vs 6%. New Euro-US perioperative backbone, on top of which all subsequent perioperative IO layering (MATTERHORN / KEYNOTE-585 FLOT subgroup) is built.
JACCRO GC-07 [PMID 30925125] (Yoshida 2019 J Clin Oncol, N=915, Japan): stage III D2 postoperative S-1 + docetaxel vs S-1 monotherapy. 3-year RFS 66% vs 50% (HR 0.632, P<0.001). Definitive evidence for Japanese stage III adjuvant doublet; “add docetaxel for stage III” written into Japanese guidelines.
CRITICS [PMID 29650363] (Cats 2018 Lancet Oncol, N=788, Netherlands): preop chemo (ECC/EOC) + postop chemo vs postop CRT (45 Gy + capecitabine/cisplatin). mOS 43 vs 37 months (HR 1.01, P=0.90), negative. No benefit from adding postop CRT after preop chemo — same author team / same country as CROSS but opposite result (neoadjuvant CRT vs postadjuvant CRT), highlighting that RT timing is key.
ST03 [PMID 28163000] (Cunningham 2017 Lancet Oncol, N=1063, UK): perioperative ECX + bevacizumab vs ECX. 3-year OS 50.3% vs 48.1% (HR 1.08, P=0.36), negative; esophagogastric anastomotic leak 24% vs 10%. The attempt to “add bev to perioperative” failed completely + increased surgical complications.
PRODIGY [PMID 34133211] (Kang 2021 J Clin Oncol, N=530, Korea): neoadjuvant DOS (docetaxel + oxaliplatin + S-1) × 3 cycles + surgery + adjuvant S-1 vs surgery + adjuvant S-1. 3-year PFS 66.3% vs 60.2%, adjusted HR 0.70 (P=0.023). Definitive evidence for Korea’s “neoadjuvant DOS triplet” — a representative of Asian neoadjuvant-era regimen iteration.
RESOLVE [PMID 34252374] (Zhang 2021 Lancet Oncol, N=1094, China): locally advanced GC/GEJ D2 gastrectomy perioperative SOX vs adjuvant SOX vs adjuvant CAPOX. 3-year DFS 59.4% (perioperative SOX) vs 51.1% (adjuvant CAPOX), HR 0.77 (P=0.028); adjuvant SOX non-inferior to adjuvant CAPOX. Definitive Chinese evidence for perioperative SOX — “perioperative > pure adjuvant” confirmed by RCT in Chinese population.
G-SOX [PMID 25316259] (Yamada 2015 Ann Oncol, N=685, Japan): advanced 1L SOX (S-1 + oxaliplatin) vs CS (S-1 + cisplatin). mOS 14.1 vs 13.1 months, PFS HR 1.004 (non-inferior), SOX fewer G≥3 AEs (nephrotoxicity / neutropenia). SOX established as SP alternative in Japanese / Asian advanced 1L, providing the control-arm background for later ATTRACTION-4 / ORIENT-16.
TOPGEAR [PMID 39282905] (Leong 2024 N Engl J Med, N=574, international): perioperative chemo ± preop CRT. pCR 17% vs 8% (favoring CRT) but mOS 46 vs 49 months (HR 1.05, NS), mPFS 31 vs 32 months (NS). pCR improved but OS did not — textbook case of “pCR as surrogate endpoint is unstable in gastric cancer” (fundamentally different from the strong pCR-OS correlation in breast cancer).

Takeaway: 2026 adjuvant / perioperative SoC is geographically branched — Euro-US first-choice FLOT4 perioperative (4+4 cycles), China first-choice RESOLVE perioperative SOX, Japan stage III first-choice JACCRO GC-07 S-1 + docetaxel adjuvant, Korea first-choice CLASSIC adjuvant CAPOX or ARTIST-2 SOX 6 months, GEJ/EAC first-choice CROSS neoadjuvant CRT. US INT-0116 adjuvant chemoRT has exited Asian practice in the adequate-D2 era (ARTIST-2 closed the debate), preserved only for D0-D1 or inadequate-dissection scenarios. Three “no longer use” paths: bevacizumab perioperative (ST03 negative), postop CRT after preop chemo (CRITICS negative), and judging OS by pCR alone as surrogate (TOPGEAR lesson).

2.3 HER2 era’s 10-year leap (2010-2025): ToGA → T-DXd → KEYNOTE-811 / zanidatamab

Story: after 2010 ToGA made HER2 gastric cancer’s first biomarker pedestal, no second HER2 drug entered gastric cancer SoC for a full 10 years — LOGIC/TRIO-013 (lapatinib + CapeOx vs CapeOx) 2016 negative, TyTAN / GATSBY (T-DM1 vs paclitaxel) negative. Not until 2020 did DESTINY-Gastric-01 use trastuzumab deruxtecan (T-DXd, HER2-ADC) break the stalemate in 2L HER2+; in 2023 KEYNOTE-811 layered pembrolizumab onto trastuzumab + chemo as the new HER2+ 1L backbone; in 2025 DESTINY-Gastric-04 made T-DXd the 2L HER2+ standard (beating the 10-year RAINBOW ramucirumab + paclitaxel); in 2025 HERIZON-GEA-01 topline used zanidatamab (HER2 bispecific antibody, simultaneously binding domains 2 + 4) to challenge the trastuzumab 1L backbone.

LOGIC/TRIO-013 [PMID 26628478] (Hecht 2016 J Clin Oncol, N=545): 1L HER2+ lapatinib + CapeOx vs CapeOx. mOS 12.2 vs 10.5 months (HR 0.91, NS, negative), mPFS 6.0 vs 5.4 months (HR 0.82, P=0.0381), ORR 53% vs 39%. First failure of the HER2 small-molecule TKI path in gastric cancer — lapatinib’s “PFS wins, OS doesn’t” replayed, deepening the view that “trastuzumab is irreplaceable as the HER2 backbone in gastric cancer.”
DESTINY-Gastric-01 [PMID 32469182] (Shitara 2020 N Engl J Med, N=187, Japan/Korea): HER2+ post-trastuzumab T-DXd vs physician’s choice chemo. ORR 51% vs 14% (P<0.001), mOS 12.5 vs 8.4 months (HR 0.59, P=0.01), ILD 9 cases G1-2 / 3 cases G3-4. First positive 2L HER2+ regimen 10 years into the HER2 era, FDA accelerated approval 2021-01.
DESTINY-Gastric-02 [PMID 37329891] (Van Cutsem 2023 Lancet Oncol, N=79, US/EU): HER2+ post-trastuzumab T-DXd 6.4 mg/kg single-arm phase II. Confirmed ORR 42%, mPFS 5.6 months, mOS 12.1 months, ILD 10% (1 G5 fatality). Replicated DG-01 in Euro-US populations — cross-regional consistency of HER2+ 2L T-DXd confirmed; ILD is the key safety signal.
KEYNOTE-811 [PMID 37871604] (Janjigian 2023 Lancet, N=698): HER2+ CPS≥1 advanced 1L pembrolizumab + trastuzumab + FP/CAPOX vs placebo + trastuzumab + FP/CAPOX. mPFS 10.0 vs 8.1 months (HR 0.72, P=0.0002), mOS 20.0 vs 16.8 months (HR 0.84), ORR 72.6% vs 60.1%. First upgrade to the HER2 paradigm after 13 years — IO layered onto the HER2 backbone, CPS≥1 subgroup showing the clearest benefit (FDA 2023-11 restricted the indication to CPS≥1; prior accelerated approval was all-comer).
DESTINY-Gastric-04 [PMID 40454632] (Shitara 2025 N Engl J Med, N=494): HER2+ 2L T-DXd monotherapy vs ramucirumab + paclitaxel head-to-head. mOS 14.7 vs 11.4 months (HR 0.70, P=0.004), mPFS HR 0.74, confirmed ORR 44.3% vs 29.1%. T-DXd beat the 2L SoC for the first time (RAINBOW ramu + paclitaxel), the HER2+ 2L standard has switched — meaning HER2 testing must be redone at 2L (re-biopsy), because post-trastuzumab HER2 loss is ~30%.
HERIZON-GEA-01 (NCT05152147, ESMO 2025 LBA): HER2+ 1L zanidatamab + chemotherapy ± tislelizumab vs trastuzumab + chemotherapy. Topline 2025: both zanidatamab arms PFS HR ~0.65 vs control; zani + tisle + chemo mOS improved >7 months vs trastuzumab + chemo. Zanidatamab’s biepitope simultaneous binding + induced internalization mechanism — if the 2026 full paper confirms, trastuzumab’s 13-year HER2 backbone status could end. As of 2026-04 the full manuscript is unpublished and PMID unassigned, cited here by NCT + ESMO LBA only.

Takeaway: 2026 HER2+ advanced decision path — 1L = pembrolizumab + trastuzumab + FP/CAPOX (KEYNOTE-811, first choice for CPS≥1; CPS<1 remains trastuzumab + chemo per ToGA); 2L = T-DXd (DESTINY-Gastric-04 beat ramu + PTX); 3L+ = ramu + PTX (RAINBOW) / irinotecan / TAS-102. 2L must re-biopsy to recheck HER2 — post-trastuzumab HER2 loss is ~30%, giving T-DXd directly will fail in the HER2-loss population. Zanidatamab is the biggest 2026 suspense: if HERIZON-GEA-01 full paper 2026 confirms positive, the HER2 backbone turns over.

2.4 IO + chemo 1L rewrite (2021-2024): four phase IIIs concordantly positive

Story: in 2017 Japan/Korea’s ATTRACTION-2 made nivolumab positive in 3L+ gastric cancer (mOS 5.26 vs 4.14 months, HR 0.63), opening the gastric IO era; in 2018 KEYNOTE-061 ran pembrolizumab vs paclitaxel in 2L CPS≥1 and hit negative (HR 0.82, P=0.0421 NS), the first failure of IO monotherapy in 2L; in 2020 KEYNOTE-062 again made pembrolizumab in 1L “monotherapy non-inferior but combo not superior,” a first cold-water moment for 1L IO; not until 2021 did CheckMate-649 use nivolumab + FOLFOX/XELOX achieve mOS 14.4 vs 11.1 months (HR 0.71) in CPS≥5 — 1L IO+chemo milestone; then over 3 years KEYNOTE-859 / ORIENT-16 / RATIONALE-305 used three different PD-(L)1s (pembrolizumab / sintilimab / tislelizumab) to replicate concordantly, HRs converging in the 0.71-0.80 narrow band — class effect formally established.

ATTRACTION-2 [PMID 28993052] (Kang 2017 Lancet, N=493, Japan/Korea/Taiwan): ≥2L nivolumab vs placebo. mOS 5.26 vs 4.14 months (HR 0.63, P<0.0001), 12-month OS 26.2% vs 10.9%, ORR 11.2% vs 0%. Starting point of gastric IO — but limited to East Asian 3L+ scenarios.
KEYNOTE-061 [PMID 29880231] (Shitara 2018 Lancet, N=592): 2L CPS≥1 pembrolizumab vs paclitaxel. mOS 9.1 vs 8.3 months (HR 0.82, P=0.0421 NS, negative), CPS≥10 subgroup showed benefit signal, G≥3 TRAE 14% vs 35%. IO monotherapy 2L failure — lesson: “IO worse than chemo” holds in 2L unselected population.
KEYNOTE-062 [PMID 32880601] (Shitara 2020 JAMA Oncol, N=763): 1L CPS≥1 pembrolizumab monotherapy vs pembrolizumab + chemo vs chemo. Pembrolizumab monotherapy vs chemo mOS non-inferior (CPS≥1 10.6 vs 11.1 months), CPS≥10 subgroup 17.4 vs 10.8 months (HR 0.69 but NS), pembrolizumab + chemo vs chemo no significant OS difference. First cold water for 1L IO — revealed that “unselected + IO” is not enough; PD-L1 enrichment required.
JAVELIN Gastric 100 [PMID 33197226] (Moehler 2021 J Clin Oncol, N=499): avelumab maintenance vs continued chemo after 12-week induction chemo. mOS 10.4 vs 10.9 months (HR 0.91, P=0.178, negative), 24-month OS 22.1% vs 15.5%, TRAE ≥G3 12.8% vs 32.8%. IO maintenance strategy failed — even with the “chemo exit lowers toxicity” attraction, no OS-level win.
ATTRACTION-4 [PMID 35030335] (Kang 2022 Lancet Oncol, N=724): HER2- 1L nivolumab + SOX/CAPOX vs placebo + SOX/CAPOX. mPFS 10.45 vs 8.34 months (HR 0.68, P=0.0007), mOS 17.45 vs 17.15 months (HR 0.90, P=0.26, primary OS endpoint not met). PFS wins, OS loses — high Japan/Korea SP/SOX baseline + crossover dilution, failed to reach the global IO standard.
CheckMate-649 [PMID 34102137] (Janjigian 2021 Lancet, N=1581): HER2- 1L nivolumab + FOLFOX/XELOX vs chemo. CPS≥5 mOS 14.4 vs 11.1 months (HR 0.71, P<0.0001), mPFS 7.7 vs 6.0 months (HR 0.68), ORR 60% vs 45%. 1L IO+chemo milestone, FDA approved 2021 (initially all-comer, later restricted to CPS≥5).
ORIENT-16 [PMID 38051328] (Xu 2023 JAMA, N=650, China): HER2- 1L sintilimab + XELOX vs placebo + XELOX. All-comers mOS 15.2 vs 12.3 months (HR 0.77, P=0.009), CPS≥5 mOS 18.4 vs 12.9 months (HR 0.66, P=0.002). First domestic Chinese PD-1 to achieve phase III OS positive in advanced gastric cancer, NMPA approved 2022. Extremely high clinical penetration in China, cost ~1/3 of pembrolizumab.
KEYNOTE-859 [PMID 37875143] (Rha 2023 Lancet Oncol, N=1579): HER2- 1L pembrolizumab + FP/CAPOX vs placebo + FP/CAPOX. ITT mOS 12.9 vs 11.5 months (HR 0.78, P<0.0001), CPS≥10 HR 0.65, mPFS 6.9 vs 5.6 months (HR 0.76), ORR 51.3% vs 42.0%. All-comer positive led FDA 2023-11 to remove the CPS restriction on pembrolizumab in gastric cancer — US practice shifted from “check CPS then give pembro” to “HER2- just give pembro,” but EU and NCCN still retain CPS≥1 / ≥5 recommendations.
RATIONALE-305 [PMID 38806195] (Qiu 2024 BMJ, N=997): HER2- 1L tislelizumab + chemo vs placebo + chemo. PD-L1 TAP≥5% mOS 17.2 vs 12.6 months (HR 0.74), ITT mOS 15.0 vs 12.9 months (HR 0.80, P=0.001). China approved 2024; PD-L1 TAP (tumor area positivity) introduced as an alternative scoring method to CPS.
CheckMate-032 [PMID 30110194] (Janjigian 2018 J Clin Oncol, N=160): advanced esophagogastric nivolumab monotherapy vs nivo + ipi multi-arm early data. ORR: nivo 12% / nivo1+ipi3 24% / nivo3+ipi1 8%; 12-month OS 39% / 35% / 24%. IO + IO ipi dose signal (ipi3 > ipi1), but phase III CheckMate-649 did not pursue an ipi arm — origin of the “dual IO has not become a 1L regimen in gastric cancer” backdrop.

Takeaway: 2026 HER2- advanced 1L IO + chemo class effect established — HRs converge in the narrow 0.71-0.80 band across four PD-(L)1 regimens (nivolumab / pembrolizumab / sintilimab / tislelizumab), choice determined by biomarker CPS threshold × regional access × price × chemo backbone preference. CPS threshold regional policy divergence: FDA removed the threshold (driven by KN-859); NCCN still recommends CPS≥5; EU retains CPS≥1; China NMPA stratifies per each drug’s registered CPS. IO monotherapy 2L (KEYNOTE-061) and IO maintenance (JAVELIN Gastric 100) paths are both closed — don’t walk them again.

2.5 Biomarker triple-subtype year zero + perioperative IO + CAR-T dawn (2023-2026)

Story: 2023 has been called the “gastric biomarker revolution year” — SPOTLIGHT (Shitara, CLDN18.2 + mFOLFOX6) and GLOW (Shah, CLDN18.2 + CAPOX) both published positive phase IIIs the same year, putting zolbetuximab (anti-Claudin-18.2 isoform 2 mAb) on the new CLDN18.2+ HER2- 1L standard (global HER2- gastric cancer CLDN18.2 high-expression rate ~38%); the same year KEYNOTE-811 completed HER2+ 1L IO layering + KEYNOTE-859 removed CPS restriction + ORIENT-16 domestic PD-1 positive. These 3 directions reading out together determined that post-2023 gastric cancer biomarker testing must include the HER2 + CLDN18.2 + CPS + MSI four-panel. In 2024 ATTRACTION-5’s adjuvant IO negative + 2025 MATTERHORN’s perioperative IO positive formed a one-negative-one-positive signal with a key message: “IO requires neoadjuvant exposure to activate.” In 2025 China’s CT041-ST-01 used satri-cel (satricabtagene autoleucel, CLDN18.2 CAR-T) to pull off the world’s first solid-tumor CAR-T RCT win.

FAST [PMID 33610734] (Sahin 2021 Ann Oncol, N=161, phase II): CLDN18.2+ 1L zolbetuximab + EOX vs EOX. mPFS/mOS HR 0.44 and 0.55 (both P<0.0005), CLDN18.2 moderate/strong expression ≥70% subgroup PFS HR 0.38. Early proof-of-concept for CLDN18.2 as a druggable target, paving the way for SPOTLIGHT/GLOW.
SPOTLIGHT [PMID 37068504] (Shitara 2023 Lancet, N=565): CLDN18.2+ (IHC ≥75% 2+/3+) HER2- 1L zolbetuximab + mFOLFOX6 vs placebo + mFOLFOX6. mPFS 10.61 vs 8.67 months (HR 0.75, P=0.0066), mOS 18.23 vs 15.54 months (HR 0.75, P=0.0053). CLDN18.2 became gastric cancer’s third actionable biomarker (after HER2 and PD-L1).
GLOW [PMID 37524953] (Shah 2023 Nat Med, N=507): CLDN18.2+ HER2- 1L zolbetuximab + CAPOX vs placebo + CAPOX. mPFS 8.21 vs 6.80 months (HR 0.687, P=0.0007), mOS 14.39 vs 12.16 months (HR 0.771, P=0.0118). Concordantly replicated SPOTLIGHT — zolbetuximab class effect confirmed, mFOLFOX6 and CAPOX backbones equivalent. FDA approved 2024-10.
ILUSTRO [PMID 37490286] (Klempner 2023 Clin Cancer Res, phase II multi-cohort): CLDN18.2+ advanced zolbetuximab monotherapy (cohort 1A) / + mFOLFOX6 (cohort 2) / + pembrolizumab (cohort 3A). 1L+chemo cohort mPFS 17.8 months / ORR 71.4%; monotherapy 3L+ ORR 0%; zolbetuximab + pembrolizumab 3L+ ORR 0% / mPFS 2.96 months. Key take-home: zolbetuximab fails as monotherapy / + IO at 3L+; must be used 1L with chemo.
TRANSTAR102 cohort G (NCT04495296): high / moderate CLDN18.2 expression 1L osemitamab (TST001, anti-CLDN18.2 ADCC-enhanced antibody) + nivolumab + CAPOX phase II single-arm. Any PD-L1 subgroup mPFS 12.6 months, CPS<5 subgroup mPFS 12.6 months, ORR 66%+. Chinese domestic CLDN18.2 + IO + chemo triplet candidate regimen — PMID not yet assigned as of 2026-04, phase III ongoing.
FRUTIGA (NCT03223376, Xu 2024 published but PMID link anomalous): 2L HER2- / post-chemo fruquintinib (oral VEGFR TKI) + paclitaxel vs placebo + paclitaxel. mPFS 5.6 vs 2.7 months (HR 0.57, P<0.0001, MET), mOS 9.6 vs 8.4 months (HR 0.96, P=0.6064, OS not met), ORR 42.4% vs 22.4%. Chinese domestic VEGFR TKI 2L PFS wins, OS loses — NMPA approved 2023, but limited global impact. The PMID metadata link in yaml is anomalous (see bottom of §7.1); this section primarily indexes by NCT.
KEYNOTE-585 [PMID 40829093] (Shitara 2025 J Clin Oncol, N=1007): resectable GC/GEJ perioperative pembrolizumab + chemotherapy (cisplatin/5-FU or FLOT subgroup) vs placebo + chemotherapy. Main cohort mOS 71.8 vs 55.7 months (HR 0.86, NS), EFS HR 0.81, pathCR improved; but OS primary endpoint not met. “Perioperative IO + old FP backbone failed, FLOT subgroup signal good” — laid the hypothesis foundation for MATTERHORN using FLOT as the backbone.
MATTERHORN [PMID 40454643] (Janjigian 2025 N Engl J Med, N=948): resectable GC/GEJ durvalumab 1500 mg Q4W + perioperative FLOT × 4+4 → durvalumab Q4W × 10 vs placebo + FLOT. 2-year EFS 67.4% vs 58.5% (HR 0.71, P<0.001), pCR 19.2% vs 7.2% (RR 2.69), 2-year OS 75.7% vs 70.4% (OS maturity pending). ASCO 2025 practice-changing — IO finally entered perioperative; KN-585 lesson inherited: must use FLOT backbone, not old FP.
ATTRACTION-5 [PMID 38906161] (Kang 2024 Lancet Gastroenterol Hepatol, N=755, Japan/Korea/Taiwan): post-D2 stage III adjuvant nivolumab + S-1/CapOx vs placebo + chemo. 3-year RFS 68.4% vs 65.3% (HR 0.90, P=0.44, negative). Pure postop addition of IO does not activate immune response — in stark contrast to the positive signals from MATTERHORN / KN-585 neoadjuvant exposure. Mechanistic hypothesis: IO requires “tumor-in-situ priming” — after resection tumor antigen disappears, ICI loses its target.
CT041-ST-01 [PMID 40460847] (Qi 2025 Lancet, N=156): advanced CLDN18.2+ 3L+ satri-cel (CLDN18.2 CAR-T) vs physician’s choice chemo. mPFS 3.25 vs 1.77 months (HR 0.37, P<0.0001), ORR 37% vs 10%, mOS trend favorable. World’s first solid-tumor CAR-T RCT win, NMPA NDA accepted — gastric cancer becomes the cancer type where solid-tumor CAR-T breaks through.

Takeaway: 2026 advanced 1L biomarker subtyping must check the HER2 + CLDN18.2 + PD-L1 CPS + MSI/dMMR four-panel — HER2+ / CLDN18.2+ / CPS-high / MSI-H have low cross-overlap (each covers 15-20% / 38% / ~60% / ~5-10%); missing any one = missing a high-responding subgroup with 30-70% ORR. Perioperative IO = must be neoadjuvant-exposed + must use FLOT backbone (MATTERHORN / KN-585 dual validation); pure postop IO doesn’t work (ATTRACTION-5 negative). CLDN18.2+ 3L+ CAR-T path (CT041-ST-01) has opened the door in China; global rollout awaits NMPA NDA completion.

3. Horizontal: the 2026 decision landscape (six dimensions)

Projecting longitudinal evolution onto the concrete 2026 clinical decision tree, the following are the six key branchpoints and the evidence for each.

3.1 Newly diagnosed advanced GC/GEJ: full biomarker four-panel

NCCN Gastric V2.2025 + CSCO Gastric 2025 explicitly recommend biomarker testing for all newly diagnosed advanced GC/GEJ, covering: HER2 IHC/FISH + PD-L1 IHC (22C3 CPS or 58-8 TAP) + CLDN18.2 IHC + MSI/dMMR (IHC or PCR). A positive result in any one directly changes the 1L regimen:

HER2+ (IHC3+ or IHC2+/FISH+, ~15-20%): CPS≥1 → KEYNOTE-811 (pembrolizumab + trastuzumab + FP/CAPOX); CPS<1 → ToGA (trastuzumab + chemo)
HER2- / CLDN18.2+ (IHC ≥75% 2+/3+, ~38%): zolbetuximab + mFOLFOX6 (SPOTLIGHT) or + CAPOX (GLOW)
HER2- / CLDN18.2- / CPS≥5: nivolumab + FOLFOX/XELOX (CheckMate-649) / pembrolizumab + FP/CAPOX (KEYNOTE-859) / sintilimab + XELOX (ORIENT-16) / tislelizumab + chemo (RATIONALE-305), any of them
HER2- / CLDN18.2- / CPS<5: FOLFOX / CAPOX / SOX chemo (limited IO benefit; confirmed by KEYNOTE-062)
MSI-H / dMMR (~5-10%): IO + chemo or pembrolizumab monotherapy (MSI-H has significantly higher response rate; KEYNOTE-062 CPS≥10 subgroup was partly MSI-H–driven)

3.2 Advanced 1L landscape: four PD-(L)1 class effect + CPS threshold policy divergence

2026 mainstream: HER2- advanced 1L SoC = IO + chemo (any of four PD-(L)1s + FOLFOX/CAPOX/SOX backbone), HRs converging in the 0.71-0.80 narrow band.

Subgroup	First choice	Second choice
HER2- CPS≥5	nivolumab + FOLFOX/XELOX [CheckMate-649 PMID 34102137] or pembrolizumab + FP/CAPOX [KEYNOTE-859 PMID 37875143]	sintilimab + XELOX [ORIENT-16 PMID 38051328] (China cost advantage) / tislelizumab + chemo [RATIONALE-305 PMID 38806195]
HER2- CPS 1-4	pembrolizumab + FP/CAPOX (available after US FDA removed CPS limit)	IO not mandatory, chemo alone acceptable
HER2- CPS<1	FOLFOX / CAPOX / SOX chemo [REAL-2 PMID 18172173 / G-SOX PMID 25316259]	limited IO benefit
HER2+ CPS≥1	pembrolizumab + trastuzumab + FP/CAPOX [KEYNOTE-811 PMID 37871604]	trastuzumab + chemo [ToGA PMID 20728210]
HER2+ CPS<1	trastuzumab + FP/CAPOX [ToGA PMID 20728210]	—
HER2- CLDN18.2+	zolbetuximab + mFOLFOX6 [SPOTLIGHT PMID 37068504] or + CAPOX [GLOW PMID 37524953]	IO + chemo (if CLDN18.2 untested / negative)

CPS threshold regional policy differences: FDA removed the pembrolizumab gastric CPS threshold (based on KN-859 all-comer positive) → US HER2- full coverage; NCCN Gastric V2.2025 still recommends CPS≥5 as IO benefit marker; EU EMA retains CPS≥1; China NMPA stratifies per each drug’s registered CPS (nivolumab CPS≥5 / sintilimab CPS≥5 / tislelizumab TAP≥5% etc.).

Contraindicated / not recommended 2026: IO monotherapy 2L unselected (KEYNOTE-061 negative) + IO maintenance (JAVELIN Gastric 100 negative) + lapatinib instead of trastuzumab (LOGIC/TRIO-013 negative).

3.3 Advanced 2L+: HER2 status dominates + mandatory re-biopsy

2026 mainstream: post-IO era, 2L must first confirm HER2 status (re-biopsy), because post-trastuzumab HER2 loss is ~30%.

Population	2L first choice	3L+
HER2+ post-trastuzumab (confirmed still HER2+)	T-DXd [DESTINY-Gastric-04 PMID 40454632] (mOS 14.7 months, HR 0.70)	ramucirumab + paclitaxel [RAINBOW PMID 25240821] / TAS-102 [TAGS PMID 30355453] / irinotecan
HER2-, IO-exposed (mainstream)	ramucirumab + paclitaxel [RAINBOW PMID 25240821] (mOS 9.6 vs 7.4 months, HR 0.807)	docetaxel + ASC [COUGAR-02 PMID 24332238] / TAS-102 / ramucirumab monotherapy [REGARD PMID 24094768]
CLDN18.2+ post-zolbetuximab	ramucirumab + paclitaxel	TAS-102 / satri-cel CAR-T [CT041-ST-01 PMID 40460847] (China pending NMPA)
CheckMate-032 multi-IO failures	chemo fallback	clinical trial
FRUTIGA (fruquintinib + paclitaxel)	China NMPA 2L option (NCT03223376, 2L HER2- CSCO Gastric 2025 Level II recommendation)	—

New challenge: since 2025 the 2L mandatory HER2 / CLDN18.2 re-biopsy workflow has low real-world execution — frontline clinicians habitually go “1L progression → 2L direct RAINBOW,” with high missed-diagnosis rates.

3.4 Adjuvant / perioperative: five East–West paths that never meet

2026 mainstream: geographically branched, no unified global SoC.

Region	Perioperative / adjuvant SoC (2026)	Key evidence
North America / Western Europe (GC majority)	Perioperative FLOT × 4+4 + perioperative durvalumab [MATTERHORN PMID 40454643] (2-year EFS 67.4%)	FLOT4 [PMID 30982686] upgraded backbone to FLOT; MATTERHORN layered IO on top
GEJ/EAC (global)	Neoadjuvant CRT (CROSS regimen) + surgery [CROSS PMID 22646630] (mOS 49.4 months)	Global GEJ tri-modality SoC; Neo-AEGIS [PMID 37734399] did not falsify it
Japan (mostly stage III)	D2 postoperative S-1 + docetaxel adjuvant [JACCRO GC-07 PMID 30925125] (3y RFS 66%)	Japanese “adjuvant-first” tradition + neoadjuvant option PRODIGY [PMID 34133211]
Korea (stage II-III)	D2 postoperative CAPOX adjuvant [CLASSIC PMID 22226517] or SOX adjuvant [ARTIST-2 PMID 33278599]	Doublet chemo sufficient; ARTIST-2 closed post-D2 RT debate
China (locally advanced)	Perioperative SOX [RESOLVE PMID 34252374]	China post-D2 first choice perioperative SOX (HR 0.77 vs adjuvant CAPOX)
Residual disease post-CROSS (any region)	Adjuvant nivolumab 1 year [CheckMate-577 PMID 33789008] (mDFS 22.4 vs 11.0 months)	ASCO 2025 mature OS shows benefit concentrated in PD-L1+ subgroup; ITT OS not significant
Not recommended	bevacizumab perioperative [ST03 PMID 28163000] / postop CRT after preop chemo [CRITICS PMID 29650363] / pure postop IO [ATTRACTION-5 PMID 38906161] / preop CRT on top of perioperative chemo [TOPGEAR PMID 39282905] (pCR improved, OS did not)	All four falsified

Current status of INT-0116 adjuvant chemoRT: 15-year US SoC initially, exited Asian practice in the adequate-D2 era (ARTIST-2 closed debate); US retains for D0-D1 / inadequately-dissected nodes.

The “death” of MAGIC: the 2006 MAGIC ECF perioperative backbone was replaced by FLOT after 2019 FLOT4; ECF is used only occasionally for “FLOT-intolerant” patients, no longer SoC.

3.5 Perioperative IO: MATTERHORN positive + key lessons

2026 mainstream: MATTERHORN [PMID 40454643] 2-year EFS 67.4% vs 58.5% (HR 0.71) + pCR 19.2% vs 7.2% → durvalumab + FLOT perioperative becomes the new North America / Western Europe SoC candidate (FDA 2025-2026 expected approval; as of 2026-04 mature OS not yet reached).

Key lesson 1 (backbone determines IO effect): KEYNOTE-585 [PMID 40829093] used old FP backbone, perioperative pembrolizumab mOS 71.8 vs 55.7 months but NS; MATTERHORN used new FLOT backbone + durvalumab 2-year EFS positive. “Perioperative IO must use FLOT backbone” written into 2025 ASCO consensus.

Key lesson 2 (IO needs neoadjuvant exposure): ATTRACTION-5 [PMID 38906161] pure postop nivolumab + S-1/CapOx adjuvant 3-year RFS 68.4% vs 65.3% (HR 0.90, negative); vs MATTERHORN’s neoadjuvant + adjuvant durvalumab positive — “postop-only IO does not activate immunity,” mechanistic hypothesis: ICI needs tumor-in-situ antigen priming.

Key lesson 3 (pCR ≠ OS): TOPGEAR [PMID 39282905] pCR 17% vs 8% improved but mOS no difference (HR 1.05, NS); KEYNOTE-585 [PMID 40829093] pCR improved but ITT OS NS. “Gastric pCR as surrogate is unstable” — fundamentally different from the strong pCR-OS correlation in breast cancer; clinical trial design needs caution.

3.6 Surgical technique: D2 + laparoscopic consensus + robotic undecided

From 2015-2022 five consecutive laparoscopic phase IIIs (KLASS-01 / KLASS-02 / CLASS-01 / JLSSG0901 / LOGICA) established laparoscopic ≈ open D2 gastrectomy equivalence; two extended-surgery trials — D2+PAND (JCOG9501) and bursectomy (JCOG1001) — were buried.

Category	Standard regimen	Key evidence
Lymph node dissection	D2	JCOG9501 [PMID 18669424] (5-year OS 69.2% vs 70.3%, D2+PAND HR 1.03, no benefit + longer operating time / more blood loss)
Early GC (stage I) distal gastrectomy	Laparoscopic = open	KLASS-01 [PMID 30730546] (5-year OS 94.2% vs 93.3%, non-inferior)
Locally advanced GC distal gastrectomy	Laparoscopic = open	KLASS-02 [PMID 35857305] (5-year OS 88.9% vs 88.7%), CLASS-01 [PMID 31135850] (3-year DFS 76.5% vs 77.8%, non-inferior), JLSSG0901 [PMID 36920382] (5-year RFS 73.9% vs 75.7%, non-inferior)
European total / subtotal gastrectomy	Laparoscopic = open (short-term)	LOGICA [PMID 34581617] (LOS 7 days / both arms, LG less blood loss)
Bursectomy	Abandoned	JCOG1001 [PMID 36369984] (5-year OS 74.9% vs 76.5%, HR 1.03, more abdominal abscesses)
Robotic	Undecided	No phase III oncologic RCT evidence yet

4. Research Gaps: ten unsolved clinical questions

This report identifies the following gaps, each a definable concrete question (not the cliché “more research needed”):

CPS threshold global non-uniformity + real-world execution: FDA removed the pembrolizumab gastric CPS threshold + NCCN retains CPS≥5 + EU CPS≥1 + China NMPA stratifies per drug. Frontline clinicians see multiple thresholds on the same guideline page → real-world PD-L1 IHC (22C3 vs 58-8 TAP) assay differences also unresolved. Unification needed.
No head-to-head among three / four PD-(L)1s (nivolumab / pembrolizumab / sintilimab / tislelizumab) in HER2- 1L: HRs in the 0.71-0.80 narrow band, cross-trial indistinguishable. Choice depends entirely on access × price × CPS threshold × chemo backbone preference.
Is the CLDN18.2 moderate / high-expression threshold optimal: SPOTLIGHT / GLOW enrolled at IHC ≥75% 2+/3+; FAST subgroup ≥70% moderate-strong expression had better PFS HR. Different thresholds may identify different benefit populations — prospective threshold-exploration trials needed.
Is CLDN18.2 × IO combination superior to either alone: ILUSTRO 3L+ zolbetuximab + pembrolizumab cohort ORR 0% (failed); TRANSTAR102 cohort G 1L osemitamab + nivolumab + CAPOX 12.6-month PFS (signal). 1L head-to-head CLDN18.2 + IO + chemo vs CLDN18.2 + chemo has not been done.
1L choice for HER2+ CPS<1 subgroup: KEYNOTE-811 CPS<1 subgroup HR near 1.0, but FDA 2023-11 restricted to CPS≥1 rather than fully excluding CPS<1. Practice remains inconsistent on whether HER2+ CPS<1 uses ToGA or KN-811.
Backbone dependence of perioperative IO: MATTERHORN FLOT + durvalumab positive vs KEYNOTE-585 FP + pembrolizumab negative. Is it the FLOT backbone contribution or an IO mechanism difference? Independent confirmations from perioperative nivolumab + FLOT (CheckMate-Gastric Adjuvant ongoing) and pembrolizumab + FLOT subgroup (KN-585 FLOT subgroup) need time.
Why pure postop adjuvant IO failed in ATTRACTION-5: the mechanistic hypothesis is “tumor-in-situ priming” but has not been directly validated. If future biomarkers can identify “postop still IO-suitable” subgroups (e.g., ctDNA+ residual / MSI-H status), adjuvant IO could restart.
pCR as gastric surrogate endpoint is unstable: both TOPGEAR + KEYNOTE-585 were pCR-positive / OS-negative. Clinical trial design must use pCR as primary endpoint cautiously. Alternative candidates: EFS, ctDNA clearance kinetics.
The five East–West perioperative / adjuvant paths (FLOT4 / RESOLVE / CLASSIC / ARTIST-2 / JACCRO GC-07) have never been head-to-head: each path ran its own phase III in its own country vs surgery alone / old regimen, with no RCTs between them. Real-world OS differences are population differences vs regimen differences? Undistinguishable.
Global rollout path for CLDN18.2 + CAR-T: CT041-ST-01 China phase II positive + NMPA NDA accepted; global phase III and Euro-US regulatory paths not yet launched as of 2026. Whether solid-tumor CAR-T’s gastric breakthrough can extend to other CLDN18.2+ solid tumors (pancreatic, biliary) is unknown.

5. Latest 2024-2026 developments

5.1 FDA / NMPA new approvals (gastric-relevant excerpts)

Drug	Agency	Date	Indication / supporting trial
pembrolizumab + trastuzumab + chemo	FDA	2023-11 (CPS≥1 restricted)	1L HER2+ GC/GEJ / KEYNOTE-811 [PMID 37871604]
pembrolizumab + chemo (CPS restriction removed)	FDA	2023-11	1L HER2- GC/GEJ / KEYNOTE-859 [PMID 37875143]
tislelizumab + chemo	NMPA	2024	1L HER2- PD-L1 TAP≥5% / RATIONALE-305 [PMID 38806195]
zolbetuximab + mFOLFOX6 / CAPOX	FDA	2024-10-18	1L HER2- CLDN18.2+ / SPOTLIGHT + GLOW [PMID 37068504 + 37524953]
T-DXd (trastuzumab deruxtecan) 2L	FDA	2025 (expanded indication after DG-04)	2L HER2+ GC/GEJ / DESTINY-Gastric-04 [PMID 40454632]
durvalumab + perioperative FLOT	FDA	2025-2026 (pending, expected approval)	Perioperative GC/GEJ / MATTERHORN [PMID 40454643]
satri-cel (CLDN18.2 CAR-T)	NMPA	2025-2026 (NDA accepted)	3L+ CLDN18.2+ GC/GEJ / CT041-ST-01 [PMID 40460847]
fruquintinib + paclitaxel 2L	NMPA	2023	2L HER2- GC/GEJ / FRUTIGA (NCT03223376)

5.2 Key meeting readouts (2025-2026, flagged as lower-weight)

The following are candidate pool only pending formal peer review, not in the main library.

HERIZON-GEA-01 (ESMO 2025 LBA): zanidatamab + chemo ± tislelizumab vs trastuzumab + chemo 1L HER2+ positive, mOS improvement >7 months. Full manuscript unpublished as of 2026-04; if confirmed positive within 2026 → HER2 backbone turnover.
MATTERHORN mature OS (ASCO 2025 [PMID 40454643]): 2-year OS 75.7% vs 70.4% (early signal), mature OS 2026-2027 readout.
CheckMate-577 mature OS (ASCO 2025 [PMID 33789008] data): ITT OS not significant; PD-L1+ subgroup benefit — suggests post-CROSS adjuvant IO should be restricted to PD-L1+.
KEYNOTE-585 final analysis (2025 JCO [PMID 40829093]): FLOT subgroup EFS positive signal confirmed by MATTERHORN; FP subgroup OS NS closed the old backbone + IO path.
CT041-ST-01 mOS (Lancet 2025 [PMID 40460847]): mOS trend favorable, data maturing.
TRANSTAR102 cohort G (NCT04495296, ESMO 2024 oral): osemitamab + nivolumab + CAPOX 1L phase II signal good; phase III launched in China.

5.3 Ongoing phase IIIs (2026-2028 readout highlights)

HERIZON-GEA-01 full readout (NCT05152147): 2026 mature OS will determine whether zanidatamab can replace trastuzumab as the HER2+ 1L backbone
osemitamab phase III (NCT05980416 or successor): CLDN18.2+ 1L triplet vs IO + chemo head-to-head
satri-cel global phase III: CLDN18.2 CAR-T expansion outside China
ctDNA-guided adjuvant de-escalation: after ATTRACTION-5 negative, whether ctDNA+ postop residual can identify IO-responsive subgroups — early design
Perioperative IO + CLDN18.2 combination: after MATTERHORN success, CLDN18.2 + perioperative FLOT + IO triplet is the natural next step

6. Synthesis insights and judgments

6.1 Longitudinal × horizontal: 2026 gastric landscape shaped by three subtyping revolutions

Overlaying longitudinal paradigm evolution with the current horizontal decision landscape, the 2026 gastric cancer landscape is a stack of three subtyping revolutions:

Biological meaning of anatomical subtyping made manifest: 2006 MAGIC / 2012 CROSS / 2021 CheckMate-649 step by step pushed “GEJ vs gastric body” from crude endoscopic split to molecular biological subtyping in the IO era — CheckMate-649 subgroup analysis showed GEJ/EAC HR differs from pure gastric body HR (the former ~0.75, the latter ~0.65), suggesting the GEJ microenvironment responds less well to IO. In 2026 GEJ 1L decisions have gone from “treat as gastric cancer” to “Siewert II-III → gastric / Siewert I → esophageal” + perioperative choice CROSS (GEJ) vs MATTERHORN (gastric body majority). This is gastric cancer’s first subtyping revolution.
Persistent East–West path divergence: INT-0116 (US adjuvant chemoRT) / MAGIC → FLOT4 (European perioperative) / CLASSIC (Korean adjuvant CAPOX) / ACTS-GC (Japanese adjuvant S-1) / RESOLVE (Chinese perioperative SOX) — five paths, each completing phase III in its own population, never head-to-head. 2026 practice is not a “unified global SoC” but “choose path by patient’s country / region.” Regional differences + genetic background (DPYD polymorphisms) + reimbursement policies together shape the reality of “East and West never meet.” This is gastric cancer’s second subtyping revolution.
HER2 drug 10-year leap + biomarker four-layer subtyping: 2010 ToGA (trastuzumab + chemo) → 2020 DESTINY-Gastric-01 (T-DXd 2L) → 2023 KEYNOTE-811 (pembro + trastuzumab + chemo 1L) → 2025 DESTINY-Gastric-04 (T-DXd 2L SoC) → 2025 HERIZON-GEA-01 (zanidatamab challenging trastuzumab) — 5 steps in 15 years, HER2 drugs moved from binary targeting to full ADC + IO combo + bispecific coverage. Concurrently CLDN18.2 (SPOTLIGHT / GLOW) + PD-L1 CPS + MSI joined the subtyping grid → HER2 / CLDN18.2 / CPS / MSI four-layer checkerboard decides 1L regimen. This is gastric cancer’s third subtyping revolution and the direct source of the 2026 “check the full biomarker panel first” imperative.

These three revolutions together explain a clinical observation: the 1L decision tree for a newly diagnosed stage IV GC/GEJ patient in 2026 has 4 more decision layers than in 2016 (biomarker panel HER2/CPS/CLDN18.2/MSI → anatomical subtyping GEJ vs gastric body → regional access sintilimab/pembro/nivo/tislelizumab → CPS threshold FDA vs NCCN vs EU). This “deep and wide” decision tree is far more complex than HCC’s “shallow and narrow” (four-way tie within a narrow HR band) — the result of NCCN-level research density plus multinational domestic-drug co-action.

6.2 Clinical decision takeaways (for junior-mid oncologists)

In 2026 the first gastric cancer step is not the chemo regimen — it is a full biomarker panel: HER2 IHC/FISH + PD-L1 CPS + CLDN18.2 IHC + MSI/dMMR must be complete before 1L. Missing any one = missing a high-responding subgroup with 30-70% ORR.
HER2+ 1L standard upgraded since 2023: CPS≥1 use pembrolizumab + trastuzumab + FP/CAPOX (KEYNOTE-811); CPS<1 still trastuzumab + chemo (ToGA). Don’t use ToGA alone for CPS≥1 patients anymore.
CLDN18.2+ HER2- 1L SoC is zolbetuximab + mFOLFOX6/CAPOX: written into NCCN V2.2025 after FDA 2024-10 approval. Missing CLDN18.2 at 1L is the most frequent 2026 gastric cancer clinical error.
Use CPS thresholds per country: US FDA removed the pembrolizumab gastric CPS threshold; NCCN still recommends CPS≥5; EU CPS≥1; China NMPA stratifies per drug. Use the corresponding threshold in your own reimbursement / registration context.
Both IO monotherapy 2L and IO maintenance are closed: KEYNOTE-061 (2L unselected) and JAVELIN Gastric 100 (maintenance) both negative — don’t walk these two paths.
2L must re-biopsy to recheck HER2 + CLDN18.2: post-trastuzumab HER2 loss is ~30%; CLDN18.2 subgroup has similar phenomenon. “1L progression → 2L direct RAINBOW” is the biggest real-world missed-diagnosis source.
HER2+ 2L new standard is T-DXd (DESTINY-Gastric-04 beat RAINBOW): but ILD is the key safety alarm, needing baseline chest CT + dynamic monitoring + timely drug discontinuation.
The perioperative IO era has arrived: North America / Western Europe 2026 expected MATTERHORN (durvalumab + FLOT perioperative) approval; must use FLOT backbone + must have neoadjuvant exposure — both lessons have trial evidence (KN-585 FP backbone failure / ATTRACTION-5 pure postop IO failure) as controls.
Respect regional East–West paths: US walks INT-0116 + FLOT4 → MATTERHORN; Europe walks MAGIC → FLOT4 → MATTERHORN; China walks RESOLVE SOX; Japan walks JACCRO GC-07 S-1 + docetaxel; Korea walks CLASSIC CAPOX / ARTIST-2 SOX. Don’t simply extrapolate one country’s data to another.
Zanidatamab is the biggest 2026 suspense: if HERIZON-GEA-01 full paper 2026 is positive, trastuzumab’s 13-year HER2 backbone could end. Frontline clinicians’ HER2 treatment choices will face a new branchpoint — stay tuned.

7. Information sources

All 58 trial metadata in this report were independently verified via PubMed and ClinicalTrials.gov. Each [PMID xxxxxxxx] in the text is directly verifiable on PubMed.

Published trials: 58, covering 2001-2026
PMID coverage: 56 unique PMIDs (HERIZON-GEA-01 / TRANSTAR102 cohort G are ESMO LBA, PMID pending full manuscript; MAGIC / INT-0116 / CROSS have no NCT because they predate the mandatory NCT registration era)
FDA / NMPA new approvals: 8 key approvals (2023-2026)
2025-2026 key meeting / long follow-up readouts: 6 (HERIZON-GEA-01 / MATTERHORN mature OS / CheckMate-577 mature OS / KN-585 final / CT041-ST-01 / TRANSTAR102)
Research gaps: 10
China-led research proportion: ~25% (ORIENT-16 / FRUTIGA / RESOLVE / CT041-ST-01 / TRANSTAR102 / part of CLASSIC / CLASS-01 etc.)

7.1 Text citation list (by ascending PMID)

The following table is the PMID list of all bracket citations in the text + summary tables; each can be clicked to verify on PubMed.

PMID	First Author	Year	Journal	Trial / topic
11547741	Macdonald JS	2001	N Engl J Med	INT-0116 adjuvant chemoRT
16822992	Cunningham D	2006	N Engl J Med	MAGIC perioperative ECF
17075117	Van Cutsem E	2006	J Clin Oncol	V325 advanced DCF
17978289	Sakuramoto S	2007	N Engl J Med	ACTS-GC Japanese adjuvant S-1
18172173	Cunningham D	2008	N Engl J Med	REAL-2 (ECF/ECX/EOF/EOX)
18282805	Koizumi W	2008	Lancet Oncol	SPIRITS Japanese advanced SP
18669424	Sasako M	2008	N Engl J Med	JCOG9501 D2 vs D2+PAND
20728210	Bang YJ	2010	Lancet	ToGA HER2+ trastuzumab
22226517	Bang YJ	2012	Lancet	CLASSIC Asian adjuvant CAPOX
22646630	van Hagen P	2012	N Engl J Med	CROSS GEJ neoadjuvant CRT
24094768	Fuchs CS	2014	Lancet	REGARD 2L ramucirumab
24332238	Ford HE	2014	Lancet Oncol	COUGAR-02 2L docetaxel
25240821	Wilke H	2014	Lancet Oncol	RAINBOW 2L ramu + paclitaxel
25316259	Yamada Y	2015	Ann Oncol	G-SOX advanced SOX vs CS
25559811	Park SH	2015	J Clin Oncol	ARTIST D2 postop XP ± RT
26628478	Hecht JR	2016	J Clin Oncol	LOGiC/TRIO-013 lapatinib negative
28163000	Cunningham D	2017	Lancet Oncol	ST03 perioperative ECX + bev negative
28993052	Kang YK	2017	Lancet	ATTRACTION-2 3L+ nivolumab
29650363	Cats A	2018	Lancet Oncol	CRITICS postop CRT negative
29880231	Shitara K	2018	Lancet	KEYNOTE-061 2L pembro negative
30110194	Janjigian YY	2018	J Clin Oncol	CheckMate-032 nivo ± ipi multi-arm
30355453	Shitara K	2018	Lancet Oncol	TAGS 3L+ TAS-102
30730546	Kim HH	2019	JAMA Oncol	KLASS-01 early GC LDG
30925125	Yoshida K	2019	J Clin Oncol	JACCRO GC-07 S-1 + docetaxel
30982686	Al-Batran SE	2019	Lancet	FLOT4 perioperative FLOT vs ECF
31135850	Yu J	2019	JAMA	CLASS-01 LDG vs ODG
32469182	Shitara K	2020	N Engl J Med	DESTINY-Gastric-01 2L T-DXd
32880601	Shitara K	2020	JAMA Oncol	KEYNOTE-062 1L cold water
33197226	Moehler M	2021	J Clin Oncol	JAVELIN Gastric 100 maintenance negative
33278599	Park SH	2021	Ann Oncol	ARTIST-2 Korea D2 postop
33610734	Sahin U	2021	Ann Oncol	FAST phase II CLDN18.2 early
33789008	Kelly RJ	2021	N Engl J Med	CheckMate-577 GEJ adjuvant nivolumab
34102137	Janjigian YY	2021	Lancet	CheckMate-649 milestone
34133211	Kang YK	2021	J Clin Oncol	PRODIGY neoadjuvant DOS
34252374	Zhang X	2021	Lancet Oncol	RESOLVE China perioperative SOX
34581617	van der Veen A	2021	J Clin Oncol	LOGICA Europe LG vs OG
35030335	Kang YK	2022	Lancet Oncol	ATTRACTION-4 Japan/Korea nivo + SOX
35857305	Son SY	2022	JAMA Surg	KLASS-02 5-year OS LDG vs ODG
36369984	Kurokawa Y	2022	Br J Surg	JCOG1001 bursectomy negative
36920382	Etoh T	2023	JAMA Surg	JLSSG0901 LADG vs ODG 5-year
37068504	Shitara K	2023	Lancet	SPOTLIGHT zolbetuximab + mFOLFOX6
37329891	Van Cutsem E	2023	Lancet Oncol	DESTINY-Gastric-02 Euro-US T-DXd
37490286	Klempner SJ	2023	Clin Cancer Res	ILUSTRO phase II multi-cohort
37524953	Shah MA	2023	Nat Med	GLOW zolbetuximab + CAPOX
37734399	Reynolds JV	2023	Lancet Gastro Hepatol	Neo-AEGIS CROSS vs MAGIC/FLOT
37871604	Janjigian YY	2023	Lancet	KEYNOTE-811 HER2+ IO + HER2
37875143	Rha SY	2023	Lancet Oncol	KEYNOTE-859 all-comer
38051328	Xu J	2023	JAMA	ORIENT-16 China sintilimab
38734867	—	—	—	FRUTIGA yaml PMID link anomalous (text cites by NCT03223376)
38806195	Qiu MZ	2024	BMJ	RATIONALE-305 tislelizumab
38906161	Kang YK	2024	Lancet Gastro Hepatol	ATTRACTION-5 pure adjuvant IO negative
39282905	Leong T	2024	N Engl J Med	TOPGEAR preop CRT + perioperative chemo
40454632	Shitara K	2025	N Engl J Med	DESTINY-Gastric-04 T-DXd vs RAINBOW
40454643	Janjigian YY	2025	N Engl J Med	MATTERHORN perioperative durvalumab + FLOT
40460847	Qi C	2025	Lancet	CT041-ST-01 satri-cel CAR-T
40829093	Shitara K	2025	J Clin Oncol	KEYNOTE-585 final

7.2 Verification conventions

Each PMID is directly accessible via https://pubmed.ncbi.nlm.nih.gov/{PMID}/
Each NCT id is accessible via https://clinicaltrials.gov/study/{NCT_id}/
HERIZON-GEA-01 / TRANSTAR102 cohort G are at ESMO LBA / ASCO oral stage; PMID pending 2026 full manuscript — this report indexes by NCT
FRUTIGA (PMID 38734867) yaml data has a PubMed metadata link anomaly (the PMID corresponds to an ED medication errors review, not the FRUTIGA main publication); this report primarily indexes the text by NCT03223376, with “yaml PMID link anomalous” honestly disclosed in the §7.1 table; data fix pending v2
MAGIC / INT-0116 / CROSS have no NCT id (predate the 2004 ClinicalTrials.gov mandatory registration / UK MRC internal trial)
If you find any PMID in the report whose trial name / year / conclusion differs from PubMed, corrections are welcome

Clinical trial timeline here

Chinese: /trials/gastric/ English: /en/trials/gastric/

Each trial has its own detail page, containing:

Full intervention / comparator regimen
Primary endpoint values + 95% CI
Key findings + clinical significance
Clickable jump to PMID / NCT source

58 trials · 5 chapters · 2001 to 2026 · synced with NCCN Gastric V2.2025 + CSCO Gastric 2025 dual guidelines.

Closing

Gastric cancer over the past 25 years has completed a unique evolution in oncology — from 2001 INT-0116 putting adjuvant chemoRT on the US postoperative SoC, through the 2006 MAGIC “perioperative chemo” concept invention, 2010 ToGA HER2 as the first biomarker target, 2019 FLOT4 perioperative backbone upgrade, 2021 CheckMate-649 IO + chemo 1L standard, 2023 SPOTLIGHT / GLOW CLDN18.2 new subtype, 2025 MATTERHORN perioperative IO breakthrough, 2025 DESTINY-Gastric-04 HER2+ 2L new standard, and 2025 CT041-ST-01 solid-tumor CAR-T’s first RCT win.

The most essential difference between gastric cancer and other GI major cancers (HCC / BTC / PDAC) is “early biomarker subtyping start but severe geographic branching + HER2 drugs’ 10-year leap is the deepest single-biomarker evolution”. NSCLC’s driver panel is “10+ molecular paths horizontally parallel”; HCC is “0 biomarker, IO backbone alone”; gastric cancer walks “HER2 / CLDN18.2 / PD-L1 CPS / MSI four-layer subtyping + East–West five perioperative / adjuvant paths + multi-country PD-(L)1 class-effect narrow band” three-dimensional checkerboard. This complexity dictates the 2026 gastric decision tree’s “deep and wide” character — 4 more decision layers than HCC, one fewer than NSCLC (no driver-targeted 1L monotherapy).

The most urgent structural problems to solve in 2026 are: the clinical chaos of non-unified global CPS thresholds, unclear 1L choice for HER2+ CPS<1, mechanism validation of why perioperative IO must use FLOT backbone, whether ctDNA-guided adjuvant de-escalation can identify adjuvant-IO benefit subgroups, and the global rollout path for CLDN18.2 CAR-T. Whether the next decade’s HER2 backbone is taken over by zanidatamab (HERIZON-GEA-01 full paper), whether next-generation ADCs (e.g., T-DM1 replacement) can break through T-DXd’s ILD boundary, and whether solid-tumor CAR-T can extend from gastric cancer to other CLDN18.2+ cancer types — these three questions determine the direction of gastric cancer’s next decade.

The value of this report is not “exhaustive enumeration of all trials” (PubMed can do that) but compressing 25 years of evolution + current decisions + unsolved gaps into the cognitive bandwidth of a single read. Next time you face a newly diagnosed gastric cancer patient, every branchpoint in the decision tree has this map to consult, trace, and interrogate.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-21

NSCLC Clinical Trial Timeline · 25-Year Evolution Map

Fri, 17 Apr 2026 00:00:00 +0000

NSCLC Clinical Trial Timeline · In-depth Report

Coverage: 111 published landmark trials (all PMID-traceable) + 90 ongoing phase III + 20 FDA/NMPA 2024-2026 approvals + 21 key conference readouts

Curated by Dual Brain Lab (csilab.net)

1. One-Sentence Definition

This report maps the systemic therapy of non-small cell lung cancer (NSCLC) over the past 25 years (2002–2026) through the landmark clinical trials cited in the current NCCN NSCLC and CSCO NSCLC 2025 guidelines — providing frontline clinicians in 2026 a traceable full-view map for the “who, what, and why” of decision-making.

Iron rule: every datapoint in every trial traces back to PubMed (PMID) or ClinicalTrials.gov (NCT id). Each [PMID xxxxxxxx] in the body opens directly to PubMed for source verification.

2. Longitudinal: Five-Paradigm Evolution Timeline

NSCLC systemic therapy has gone through five paradigm shifts in the past 25 years: the chemotherapy plateau was broken by driver mutations → TKIs (tyrosine kinase inhibitors) climbed from 2L to 1L to adjuvant → immune checkpoint inhibitors (ICIs) rewrote 2L and then 1L → IO-chemo became the new backbone → perioperative IO rewrote the treatment strategy for resectable disease.

Each shift has 3–5 phase III trials that pushed the previous standard of care (SoC) to second line.

2.1 Chemotherapy Plateau (2002–2015): Established, Challenged, Replaced

Story: The OS median of chemotherapy doublets was locked at ~8 months by ECOG 1594 in 2002. That ceiling stood until driver mutations and checkpoint inhibitors finally broke it.

ECOG 1594 [PMID 11784875] (Schiller 2002 NEJM, N=1207): four platinum doublets randomized — cis+pac vs cis+gem vs cis+doc vs carbo+pac. All four OS curves completely overlapped, mOS ~7.9 months, 1-year OS 33%. The result was both a starting point and a ceiling — “no matter which doublet you pick, it doesn’t matter.”
TAX 326 [PMID 12837811] (Fossella 2003 JCO, N=1218): docetaxel+cis slightly better than navelbine+cis, mOS 11.3 vs 10.1 months. Expanded doublet options but did not break the ceiling.
JMDB / Scagliotti 2008 [PMID 18506025] (N=1725): in non-squamous NSCLC, cis+pemetrexed beat cis+gemcitabine (mOS 11.8 vs 10.4 months) — the first phase III evidence for histology-stratified therapy. From that point on, “non-squamous takes pemetrexed” entered the guidelines.
PARAMOUNT [PMID 22341744] (Paz-Ares 2012 Lancet Oncol): pemetrexed maintenance significantly extended PFS, establishing the 2012 “induction + maintenance” standard for non-squamous NSCLC.

Takeaway: the chemo backbone was refined between 2002 and 2012 (doublet → histology stratification → maintenance), but the OS ceiling did not move. After 2015, with IPASS behind, driver-negative + squamous — the “hard-to-treat” subgroups — finally got breakthroughs from IO.

2.2 EGFR TKI Era (2009–2026): 2L → 1L → Adjuvant → Unresectable III → Combo

Story: EGFR-mutation TKI therapy is the prototype story of precision oncology in lung cancer. Each TKI generation pushed median PFS ~1.5× higher, and every push came with a pivotal phase III.

IPASS [PMID 19692680] (Mok 2009 NEJM, N=1217): gefitinib vs carbo+pac in an East Asian lung adenocarcinoma population. Overall HR 0.74, but EGFR-mutant subgroup HR 0.48 and wild-type subgroup HR 2.85. The “EGFR mutation test → stratified therapy” clinical paradigm was born here.
OPTIMAL [PMID 21783417] (Zhou 2011 Lancet Oncol) + EURTAC [PMID 22285168]: erlotinib vs chemotherapy in EGFRm 1L phase III, PFS doubled (mPFS 13.1 vs 4.6 months). 2nd-gen TKI (afatinib) LUX-Lung 3/6 consolidated further.
FLAURA [PMID 29151359] (Soria 2018 NEJM, N=556): osimertinib (3rd-gen EGFR TKI) vs 1st/2nd-gen in EGFRm 1L. mPFS 18.9 vs 10.2 months, HR 0.46, with stronger CNS activity. 2019 FLAURA OS update [PMID 31751012] was the first TKI to show OS benefit (mOS 38.6 vs 31.8 months, HR 0.80).
ADAURA [PMID 32955177] (Wu 2020 NEJM, OS 2023 [PMID 37272535]): resectable IB-IIIA EGFRm NSCLC, 3-year adjuvant osimertinib vs placebo. DFS HR 0.17, OS HR 0.49. Changed EGFRm early recurrence from “wait then treat” to “eradicate residual disease.”
LAURA [PMID 38828946] (Lu 2024 NEJM): unresectable stage III EGFRm NSCLC, osimertinib consolidation post-CRT (chemoradiation) vs placebo. mPFS 39.1 vs 5.6 months, HR 0.16. Filled the gap that PACIFIC left open for EGFRm patients unsuitable for durvalumab.
FLAURA2 [PMID 37937763] (Planchard 2023 NEJM) + MARIPOSA [PMID 38924756] (Cho 2024 NEJM, OS update 2025 [PMID 40923797]): two combo regimens — osi+chemo and amivantamab+lazertinib — pushed mPFS to 25.5 / 23.7 months, beating osi monotherapy’s 16.6 months. MARIPOSA OS HR 0.75, 3-year OS 60% vs 51% — the first mature 1L EGFRm OS benefit.
MARIPOSA-2 [PMID 37879444] + TROPION-Lung01 [PMID 39250535] (Ahn 2025 JCO): ADC (antibody-drug conjugate) strategies for post-osimertinib resistance. Dato-DXd PFS HR 0.38 in the EGFR-mutant subgroup.
SACHI [PMID 41544643] (Lu 2026 Lancet): in the post-osi MET-amplified subgroup, savolitinib+osimertinib vs chemotherapy. mPFS 8.3 vs 3.6 months, HR 0.34. First randomized controlled evidence for “treat-by-resistance-mechanism.”

Takeaway: EGFRm therapy has evolved from the 2009 “TKI vs chemo” binary to a 2026 four-dimensional decision tree — “stage × line × resistance mechanism × tolerance.” Combo (FLAURA2 / MARIPOSA) and mono (FLAURA) coexist; the choice between them comes down to tolerance and disease burden.

2.3 Non-EGFR Drivers (2014–2026): From Basket to Dedicated 1L

Story: Eight drivers — ALK, ROS1, MET, KRAS, HER2, RET, BRAF, NTRK — each walked the path “accelerated approval on phase 2 → pivotal phase 3 → pushed into 1L” between 2014 and 2026, but at very different speeds.

Driver	Key trials (PMID)	Line
ALK	PROFILE 1014 [PMID 25470694] (2014) → ALEX [PMID 28586279] (2017) → CROWN [PMID 33207094] (2020, lorlatinib) → ALINA [PMID 38598794] (2024, adjuvant alectinib)	Fully in 1L + adjuvant
ROS1	PROFILE 1001 → TRIDENT-1 [PMID 38197815] (2024, repotrectinib 1L ORR 79%)	1L (repotrectinib replaces crizotinib)
MET ex14	GEOMETRY mono-1 [PMID 32877583] (capmatinib 2020) / VISION [PMID 32469185] (tepotinib 2020)	Phase II accelerated approval; no phase III; 1L still contested
KRAS G12C	CodeBreaK 100 [PMID 34096690] → CodeBreaK 200 [PMID 36764316] (sotorasib 2L) → KRYSTAL-12 [PMID 40783289] (adagrasib 2L) → divarasib 1/2 [PMID 37611121] (phase 3 pending)	2L only
HER2 exon 20	DESTINY-Lung02 [PMID 37694347] (T-DXd 2L, ORR 49%) → Beamion LUNG-1 [PMID 40293180] (zongertinib 2L, ORR 71%)	2L; 1L still chemo-IO
RET	LIBRETTO-431 [PMID 37870973] (selpercatinib 1L vs chemo+pembro, mPFS 24.8 vs 11.2 months)	1L established
BRAF V600E	PHAROS [PMID 37270692] (encorafenib+binimetinib 1L ORR 75%)	1L
NTRK	larotrectinib / entrectinib tumor-agnostic approvals	Basket, accelerated
EGFR exon 20 insertion	PAPILLON [PMID 37870976] (amivantamab+chemo vs chemo 1L, mPFS 11.4 vs 6.7 months)	1L

Takeaway: speed of 1L entry ranks as ALK > EGFR common > EGFR ex20 > ROS1 > RET > BRAF > MET ex14 ≈ HER2 ex20 > KRAS G12C. KRAS G12C is still stuck at 2L — sotorasib and adagrasib both failed to show OS benefit over docetaxel in phase III. Divarasib’s early data (ORR 53%, mPFS 13 months) may be the next 1L-KRAS breakthrough.

2.4 IO 1L (2015–2024): From 2L Trials to Backbone Rewrite

Story: IO (anti-PD-1 / anti-PD-L1) got its first NSCLC evidence in 2015 with CheckMate-017 / 057 (2L), then KEYNOTE-024 (2016) pushed it to 1L monotherapy for PD-L1 high expressors, and finally KEYNOTE-189 (2018) wrote IO+chemo into the 1L backbone.

CheckMate-017 [PMID 26028407] (squamous) + CheckMate-057 [PMID 26412456] (non-squamous) (Brahmer / Borghaei 2015 NEJM): nivolumab vs docetaxel in 2L NSCLC. OS HR 0.59 (sq) / 0.73 (non-sq). IO enters lung cancer history.
KEYNOTE-010 [PMID 26712084] (Herbst 2016 Lancet): pembrolizumab vs docetaxel in PD-L1 ≥1% 2L. Confirmed PD-L1 as a stratification biomarker.
KEYNOTE-024 [PMID 27718847] (Reck 2016 NEJM, N=305): pembrolizumab monotherapy vs chemotherapy in PD-L1 TPS ≥50% 1L. mOS 30.0 vs 14.2 months, HR 0.60. IO monotherapy 1L established. The 5-year update [PMID 33872070] shows 5-year OS 31.9% vs 16.3% — a beautifully preserved tail.
KEYNOTE-189 [PMID 29658856] (Gandhi 2018 NEJM, N=616): pembrolizumab + pemetrexed + platinum vs placebo+chemo in non-squamous 1L (regardless of PD-L1). OS HR 0.49 (0.38–0.64), OS benefit in every PD-L1 subgroup including TPS<1%. The “~8-month ceiling” of the chemo plateau was finally shattered by the IO-chemo backbone. 5-year update [PMID 36809080]: 5y OS 19.4% vs 11.3%, TPS<1% HR 0.55.
KEYNOTE-407 [PMID 30280635] (Paz-Ares 2018 NEJM): pembro+carbo+(nab-)pac vs placebo+chemo in squamous 1L. 5-year OS 18.4% vs 9.7% [PMID 36735893]. Squamous — previously stuck with only docetaxel — was rewritten.
IMpower110 [PMID 32997907] / IMpower130 / IMpower132 / IMpower150 [PMID 29863955]: atezolizumab combos. IMpower150 (atezo+bev+chemo) retains a niche role in EGFR/ALK post-TKI and liver-metastases subgroups.
CheckMate-227 [PMID 31562796] (Hellmann 2019 NEJM, 5y update 2023 [PMID 36223558]): nivolumab+ipilimumab as a “chemo-sparing” IO-IO regimen. In the PD-L1<1% subgroup, 5y OS 19% vs 7%, HR 0.72.
CheckMate 9LA [PMID 33476593] (Paz-Ares 2021 Lancet Oncol, 5y [PMID 39270380]): nivo+ipi + 2 cycles of chemo — chemo-sparing but keeping the early tumor-debulking effect of chemo, OS HR 0.66.
POSEIDON [PMID 36327426]: durvalumab + tremelimumab + chemo. In the PD-L1<1% subgroup, tremelimumab adds ~3 months of OS.

Takeaway: the core branching of 1L IO selection in 2026 is histology (sq / non-sq) × PD-L1 (<1% / 1-49% / ≥50%) × performance status × combo tolerance. KEYNOTE-189 + KEYNOTE-407 cover nearly the entire PD-L1 spectrum in non-sq and sq; CheckMate-227 / 9LA serve as “don’t want chemo” alternatives; POSEIDON offers an intensified option for PD-L1<1%. Chinese PD-1 agents (sintilimab ORIENT-11 [PMID 35917647], tislelizumab, camrelizumab) dominate in subgroups driven by price and accessibility.

2.5 Perioperative IO (2021–2026): From Adjuvant-Only to Dual-Punch

Story: IO therapy for resectable NSCLC has had 6–8 phase III readouts over 5 consecutive years since 2021. The strategy evolved from “adjuvant only” (post-op) to “neoadjuvant only” (pre-op), and on to “perioperative” (= pre-op + post-op).

IMpower010 [PMID 34555333] (Felip 2021 Lancet, 5y update [PMID 40446184]): resectable IB-IIIA, 1-year adjuvant atezolizumab vs BSC. DFS and OS both benefit in the PD-L1 ≥50% subgroup; benefit unclear for PD-L1 <50%.
KEYNOTE-091 [PMID 36108662] (O’Brien 2022 Lancet Oncol): adjuvant pembrolizumab vs placebo. DFS HR 0.76 overall, but benefit inconsistent across PD-L1 subgroups.
CheckMate 816 [PMID 35403841] (Forde 2022 NEJM, OS 2025 [PMID 40454642]): neoadjuvant nivolumab+chemo × 3 cycles vs chemo alone. pCR (pathological complete response) 24% vs 2.2%, EFS (event-free survival) HR 0.63, OS HR 0.72. First phase III OS benefit in the neoadjuvant setting.
KEYNOTE-671 [PMID 37272513] (Wakelee 2023 NEJM, OS 2024 Lancet [PMID 39288781]): perioperative (neoadjuvant pembro+chemo × 4 → post-op pembro × 13). EFS HR 0.58, OS HR 0.72 — first perioperative trial with OS benefit.
AEGEAN [PMID 37870974] (Heymach 2023 NEJM): perioperative durvalumab+chemo. EFS HR 0.68, pCR 17.2% vs 4.3%.
CheckMate 77T [PMID 38749033] (Cascone 2024 NEJM): perioperative nivo+chemo. EFS HR 0.58, pCR 25.3% vs 4.7%.
Neotorch [PMID 38227033] (Lu 2024 JAMA, China): perioperative toripalimab+chemo in stage II-III. Stage III subgroup EFS HR 0.40.
RATIONALE-315 [PMID 39581197] (Yue 2025 Lancet Respir Med): perioperative tislelizumab+chemo. pCR 40.7% vs 5.7%, EFS HR 0.56.

Takeaway: by 2026 the SoC for resectable stage II-IIIB NSCLC is firmly perioperative IO-chemo (3-4 cycles neoadjuvant + ≥1 year adjuvant IO), with pCR confirmed as a strong surrogate for EFS / OS across multiple trials. The one exception: EGFRm → ADAURA (3-year adjuvant osimertinib) and ALK+ → ALINA (adjuvant alectinib) — these two driver-positive subgroups should avoid perioperative IO.

3. Cross-Sectional: 2026 Decision Landscape (Six Dimensions)

Six dimensions cover the full decision landscape — 1L, important 2L, early stage, PD-L1 low, post-resistance, and rare drivers. Each includes mainstream regimens, areas of controversy, head-to-head / NMA (network meta-analysis) evidence, and current NCCN/CSCO tiers.

3.1 1L IO-combo Selection (EGFR/ALK-WT, PD-L1 ≥1%)

2026 mainstream: pembro+chemo (KEYNOTE-189 non-sq / KEYNOTE-407 sq) remains the global IO-chemo backbone across the PD-L1 spectrum. For PD-L1 TPS ≥50% fit patients, pembro monotherapy (KEYNOTE-024) is still guideline-preferred, but clinical practice drifts toward combo (deeper early response + less “in-hindsight regret”). IMpower150 now only applies in liver-mets and EGFR post-TKI niches. CheckMate 9LA and POSEIDON serve as chemo-sparing / CTLA-4-adding alternatives.

Key branchpoints:

Subgroup	First choice	Alternative
Non-sq PD-L1 ≥50%	pembro mono (KN-024, 5y OS 31.9%) or pembro+pem-plat (KN-189)	CheckMate-227 (PD-L1 ≥1%)
Non-sq PD-L1 1–49%	pembro+pem-plat (KN-189)	CheckMate 9LA
Squamous full PD-L1	pembro+carbo+(nab-)pac (KN-407, 5y OS 18.4% vs 9.7%)	nivo+ipi+chemo (CM-9LA)
Non-sq PD-L1 <1%	pembro+pem-plat (KN-189 TPS<1% 5y HR 0.55)	CheckMate 9LA / CheckMate-227

Head-to-head / NMA:

2025 NMA [PMID 41486797]: pembrolizumab + chemotherapy ranked highest in non-sq (SUCRA HR 0.76); in squamous, nivo+ipi+chemo ranked top (SUCRA 78.3%).
KEYNOTE-189 5y [PMID 36809080] vs KEYNOTE-407 5y [PMID 36735893]: both maintain >5-year OS benefit; squamous HR 0.71 trails non-sq HR 0.60.

Controversies: for PD-L1 ≥50%, is IO-mono ≈ IO-chemo? No H2H; cross-trial data suggest “combo has better PFS but OS converges over time.” ORIENT-11 (domestic sintilimab) vs KEYNOTE-189: large differences in population, comparator arm, and PD-L1 assay mean formal equivalence is impossible — yet in price- and access-driven Chinese practice, ORIENT-11 has already replaced it widely.

NCCN 2026: histology-matched pembro+chemo = Category 1 preferred (non-sq + sq). Pembro mono = Cat 1 only for TPS ≥50%. CheckMate 9LA = Cat 1 alternative.

CSCO 2025: pembrolizumab / sintilimab / tislelizumab + chemo = Level I recommendation (non-sq); pembrolizumab / tislelizumab / camrelizumab + chemo = Level I (squamous); PD-L1 TPS ≥50% pembro mono = Level I.

3.2 EGFRm 1L: Three-Way Fight Between Mono and Combo

2026 mainstream: EGFRm 1L has shifted from osimertinib-monotherapy era into the combo era. FLAURA2 (osi+pem-plat, mOS 47.5 months [PMID 41104938]) and MARIPOSA (ami+laz, OS HR 0.77 [PMID 40923797]) both beat osi mono on OS. Osi mono (FLAURA) survives for patients “not fit for combo” thanks to its low toxicity. MARIPOSA-2 (post-osi progression, ami+chemo ± laz [PMID 37879444]) is the new post-osi standard.

Key branchpoints:

Subgroup	Recommended
Fit + high burden / L858R	FLAURA2 or MARIPOSA (combo advantage most pronounced)
Exon 19del	MARIPOSA numerical benefit slightly larger (HR ~0.65)
CNS met at baseline	MARIPOSA intracranial PFS HR 0.69; osi mono also has sufficient CNS activity
Elderly / low burden	osi mono (FLAURA) — avoids chemo toxicity (FLAURA2 G3+ AE 64%) and ami infusion / VTE burden
Post-osi progression	MARIPOSA-2 (ami+carbo-pem ± laz) Cat 1; MET-amplified → SACHI (savolitinib+osi) [PMID 41544643]

Head-to-head / NMA:

No direct FLAURA2 vs MARIPOSA H2H. Cross-trial: mPFS 25.5 vs 23.7 months, 3y OS 63% vs 60%, but toxicity profiles are entirely different (ami: rash / VTE / infusion; chemo: marrow / neuro).
MARIPOSA VTE issue: protocol amended to require prophylactic anticoagulation in the first 4 months; real-world implementation is uneven.

Controversy: is the combo OS benefit worth the doubled toxicity? The answer is patient-specific — there is no universal winner; patient choice is the core variable.

NCCN 2026: EGFRm 1L Cat 1 options = (a) ami+laz (b) osi+pem-plat (c) osi mono — all three listed without ranking.

CSCO 2025: osi mono = Level I (wide accessibility); FLAURA2 + amivantamab-based combos = Level II (pending NRDL inclusion).

3.3 Perioperative IO: Choosing Among Three Strategies

2026 mainstream: perioperative (3-4 cycles pre-op IO-chemo + ≥1 year post-op IO) has replaced adjuvant-only and neoadjuvant-only as SoC for resectable stage II-IIIB NSCLC. Five phase III trials — KEYNOTE-671 / AEGEAN / CheckMate 77T / Neotorch / RATIONALE-315 — consistently show EFS HR 0.56–0.68, and OS benefit has emerged (KEYNOTE-671 OS HR 0.72 [PMID 39288781]).

Key branchpoints:

Subgroup	Recommended
Stage II-IIIB PD-L1 ≥1% resectable	perioperative pembro+chemo (KN-671) or nivo+chemo (CM-77T) preferred
Stage II-IIIB PD-L1 <1% resectable	perioperative IO-chemo still benefits but magnitude is smaller (CM-77T PD-L1<1% EFS HR 0.73); weigh IO duration
Stage IB-IIA small tumor	neoadjuvant-only (CM-816) reasonable; or post-op adjuvant IMpower010 / KN-091
EGFRm resectable	adjuvant osimertinib (ADAURA DFS HR 0.17, OS HR 0.49). Do not use perioperative IO (all 5 perioperative trials excluded EGFRm)
ALK+ resectable	adjuvant alectinib (ALINA DFS HR 0.24 [PMID 38598794]). Same rule — avoid IO
Borderline unresectable	perioperative IO-chemo may convert to resectable; multidisciplinary decision

Controversies:

Neoadjuvant-only vs perioperative — no direct RCT. Indirect comparisons favor perioperative, but adjuvant IO adds 6-9 months of treatment and toxicity.
pCR as surrogate: strongly correlated with EFS / OS in KEYNOTE-671 and CM-816, but FDA has not formally accepted it as a standalone endpoint for accelerated approval.
ctDNA clearance as a new surrogate: in KN-671, pCR rate was 47% in ctDNA-negative patients vs 8% in ctDNA-positive.
Does everyone need adjuvant IO? De-escalation trials are in design (continue adjuvant based on ctDNA or pCR status).

NCCN 2026: resectable stage II-IIIB (EGFR/ALK-WT) = perioperative pembro+chemo (KN-671) / nivo+chemo (CM-77T) / durva+chemo (AEGEAN) Cat 1 preferred.

3.4 PD-L1 TPS <1% Subgroup

Mainstream: IO-chemo combo (KEYNOTE-189 non-sq TPS<1% 5y HR 0.55; KEYNOTE-407 sq TPS<1% HR ~0.79) remains standard. CheckMate-227 (nivo+ipi in PD-L1<1%, 5y OS 19% vs 7%) is a chemo-sparing alternative. POSEIDON shows tremelimumab adds ~3 months of OS in PD-L1<1% but is regionally constrained. Pure chemo is now inferior in every subgroup.

Controversies:

Is the KEYNOTE-189 PD-L1 TPS<1% OS benefit real IO contribution or immortal-time bias? The 5-year follow-up strengthens the IO signal, but subgroup HR confidence intervals are wide.
Do chemo-sparing IO-IO regimens (CM-227 / CM-9LA) truly beat full-dose IO-chemo in PD-L1<1%? No direct H2H; 9LA has higher immune toxicity but less marrow toxicity.
Is tremelimumab’s ~3-month OS gain in POSEIDON worth the toxicity? Real-world uptake is low.
PD-L1 <1% is a heterogeneous population (true biology vs assay false-negative) — biomarker refinement is a gap.

3.5 EGFR / ALK Post-Resistance

2026 mainstream: post-osi splits into resistance-mechanism-matched paths —

MET-amplified (12–30%) → savolitinib+osi (SACHI [PMID 41544643], mPFS 8.3 months), NMPA-approved 2026; global use is off-label.
MET overexpressing (no amplification) → telisotuzumab vedotin (LUMINOSITY [PMID 38843488], ORR 35%), FDA accelerated (Emrelis).
Unselected broad-spectrum → MARIPOSA-2 ami+chemo±laz (mPFS 6.3–8.3 months), Cat 1.
Any EGFRm post-chemo → datopotamab deruxtecan (TROPION-Lung01 [PMID 39250535], EGFRm subgroup PFS HR 0.38).
CNS-only progression → local therapy (SRS) + continue osi.

Post-lorlatinib ALK+: no approved targeted therapy. Chemo+IO is the fallback. 4th-gen ALK TKIs (NVL-655 etc.) remain in early-phase trials.

Important update: patritumab deruxtecan (HER3-DXd) HERTHENA-Lung01 [PMID 37689979] confirmed activity (ORR 29.8%), but Daiichi discontinued phase 3 NSCLC development in 2024 — not commercially available in 2026.

3.6 Rare Drivers: 1L Entry Status for 8 Branches

Driver	1L entry?	Key evidence
ALK	In	CROWN 5y PFS 60% [PMID 38819031], lorlatinib best
ROS1	In	TRIDENT-1 repotrectinib ORR 79% [PMID 38197815], best CNS activity
EGFR common	In	osi / osi+chemo / ami+laz, three-way choice
EGFR ex20	In	PAPILLON ami+chemo mPFS HR 0.40 [PMID 37870976]
RET fusion	In	LIBRETTO-431 selpercatinib vs chemo+pembro HR 0.46 [PMID 37870973]
BRAF V600E	In	PHAROS enco+bini ORR 75% [PMID 37270692]
MET ex14	Partial	capmatinib / tepotinib on phase II accelerated approval; no phase III
HER2 ex20	Not yet	2L T-DXd (DESTINY-Lung02) / zongertinib (Beamion LUNG-1); 1L still chemo-IO
KRAS G12C	Not yet	sotorasib (CB-200) / adagrasib (KRYSTAL-12) 2L PFS benefit but OS not significant; divarasib (phase 3 ongoing) may break through
NTRK	Basket	larotrectinib / entrectinib tumor-agnostic accelerated

China approval lag (2026): repotrectinib approved in China 2025 (2 years after US), selpercatinib 2023, amivantamab 2025. Glecirasib (China-domestic KRAS G12C TKI) approved ahead of FDA-divarasib — a rare reversal.

NMPA-only drugs (China-exclusive): aumolertinib (3rd-gen EGFR TKI), furmonertinib, ensartinib, toripalimab, sintilimab, tislelizumab, camrelizumab, sugemalimab, penpulimab, cadonilimab (AK104, PD-1+CTLA-4 bispecific).

4. Research Gaps: 10 Unsolved Clinical Questions

The gaps below are specifically defined questions (not “more research is needed” clichés):

EGFRm 1L: FLAURA2 (osi+chemo) vs MARIPOSA (ami+laz) has no prospective H2H; clinicians are forced into cross-trial comparison while toxicity profiles are entirely different.
PD-L1 TPS<1% NSCLC: is the KEYNOTE-189 PD-L1-negative subgroup OS benefit real IO contribution, or is it confounded by control-arm crossover + immortal-time bias? A dedicated PD-L1-negative RCT is needed.
Perioperative IO de-escalation: is the adjuvant IO phase necessary for all patients, or only for ctDNA-positive / non-pCR patients? De-escalation trials are missing.
Post-lorlatinib ALK+ NSCLC: no approved targeted therapy; ~40% of relapses are driven by compound ALK mutations; 4th-gen ALK TKIs (NVL-655 etc.) in early trials.
KRAS G12C 1L: none of sotorasib / adagrasib / divarasib / glecirasib has phase 3 1L data beating IO-chemo — all remain 2L.
Biomarker-driven ADC sequencing: HER3 / TROP2 / c-MET expression thresholds across Dato-DXd / patritumab-DXd / teliso-V are not standardized; usage is empirical.
Chinese PD-1 inhibitors (sintilimab / tislelizumab / camrelizumab / toripalimab) vs pembrolizumab: each has independent phase 3 data but no H2H; price-vs-outcome decisions have no direct evidence.
PD-L1 IHC assay variability (22C3 vs SP263 vs SP142 vs Dako 28-8): particularly at the TPS 1-49% branching point — unresolved.
IO response and co-mutation effect (STK11 / KEAP1 / SMARCA4 loss): known to reduce IO benefit but not yet routinely incorporated into clinical decision algorithms.
CNS-penetrant next-gen TKIs (lorlatinib / repotrectinib) and SRS / WBRT sequencing: no prospective definition.

5. 2024–2026 Updates

5.1 FDA / NMPA New Approvals (10 key entries of 20)

Drug	Agency	Date	Indication / Supporting trial
datopotamab deruxtecan (Datroway)	FDA	2025-06-23	2L EGFRm NSCLC post-TKI and chemo / TROPION-Lung01
lazertinib + amivantamab (Lazcluze+Rybrevant)	FDA	2024-08-19	1L EGFRm NSCLC / MARIPOSA
repotrectinib (Augtyro)	FDA	2023-11-15 (NSCLC indication expanded 2024)	ROS1+ 1L / TRIDENT-1
tarlatamab (Imdelltra)	FDA	2024-05-16	SCLC (not within NSCLC scope)
zongertinib (Hernexeos)	FDA	2025-07-10	2L HER2-mutant NSCLC / Beamion LUNG-1
savolitinib+osimertinib	NMPA	2026-01	post-osi MET-amplified / SACHI
telisotuzumab vedotin (Emrelis)	FDA	2024-05-14	c-MET high-expressor 2L EGFR-WT NSCLC / LUMINOSITY
aumolertinib	NMPA	2020 (later-line updates 2024)	EGFRm NSCLC (China-exclusive 3rd-gen TKI)
furmonertinib	NMPA	2021	EGFRm NSCLC (China-exclusive 3rd-gen TKI)
neoadjuvant pembrolizumab (KN-671)	FDA	2023-10-16	Perioperative stage II-IIIB NSCLC

(This section shows 10 key approvals; full list of 20 follows chronological order.)

5.2 Key Conference Readouts (2024–2025, Downweighted Labeling)

Entries below are candidate-pool-only until peer-reviewed publication. Those with PMIDs have been promoted to the main library.

LAURA (ASCO 2024 LBA3) [PMID 38828946]: osi consolidation post-CRT, mPFS 39.1 vs 5.6 months, HR 0.16. Fills the PACIFIC gap for stage III EGFRm.
MARIPOSA OS update (ASCO 2025) [PMID 40923797]: ami+laz vs osi OS HR 0.75, 3y OS 60% vs 51%.
FLAURA2 final OS (ESMO 2025) [PMID 41104938]: osi+chemo mOS 47.5 vs 37.0 months.
CheckMate 816 OS (WCLC 2024) [PMID 40454642]: neoadj nivo+chemo OS HR 0.72.
KRYSTAL-12 (ESMO 2024) [PMID 40783289]: adagrasib vs docetaxel 2L KRAS G12C.
SACHI (WCLC 2025) [PMID 41544643]: savo+osi post-osi MET-amplified.

(This section extracts 6 key readouts; the full conference pool has 21 non-peer-reviewed PMIDs.)

5.3 Ongoing Phase III (2025-2026 Expected Readouts)

Selected 3 representatives from 90 ongoing phase III whose primary readout is expected in 2025-2026 and is likely to change practice:

NCT04853342 FORWARD — furmonertinib vs placebo adjuvant EGFRm (Allist, China)
NCT05840016 — AK112 (ivonescimab, PD-1+VEGF bispecific) + chemo vs tislelizumab+chemo in squamous NSCLC 1L (Akeso)
NCT06617416 — AK104 (cadonilimab) vs sugemalimab in unresectable stage III NSCLC consolidation
(This section shows 3 representative readouts expected in 2025-2026; the full pool has 90 ongoing phase III.)

AK112 (ivonescimab) is the biggest 2024-2025 dark horse in Chinese lung cancer — the PD-1+VEGF bispecific is challenging pembro across multiple domestic phase III trials. HARMONi-2 (2024 WCLC) H2H: ivonescimab+chemo vs pembro+chemo mPFS 11.14 vs 5.82 months. If overseas replication succeeds, the IO-chemo backbone may be rewritten.

6. Crosspoint Insights

6.1 Longitudinal × Cross-Sectional: Three Resonances Shaping 2026

Overlaying longitudinal paradigm evolution on the cross-sectional decision landscape reveals the 2026 NSCLC picture as three layered resonances:

Chemo ceiling (mOS ~8 months) → IO-chemo backbone (mOS ~22 months) pushed driver-negative + full-PD-L1-spectrum NSCLC to 2-3× OS.
Driver stratification from 2–3 (EGFR/ALK) → 8–10 (+ ROS1/MET/KRAS/HER2/RET/BRAF/NTRK/ex20) decomposed “unselected” NSCLC into 10+ subdiseases.
Early-stage NSCLC now covered by adjuvant osi (ADAURA) + perioperative IO-chemo + adjuvant alec (ALINA) — resectable NSCLC moved from “cut and pray” to “treat by subtype.”

Together these three resonances explain a clinical phenomenon: the 1L decision tree for a newly diagnosed stage IV NSCLC patient in 2026 has 3 more decision layers than in 2016 (driver panel → PD-L1 stratification → combo intensity → China accessibility branch).

6.2 Clinical Takeaways for Junior-Mid Oncologists

“Panel first, then decide” is SoC — opening IO-chemo in 2026 without comprehensive molecular profiling is wrong; missing EGFR / ALK gives the patient the wrong regimen.
Do not give perioperative IO to EGFRm / ALK+ — all five perioperative trials excluded them. These two driver-positive subgroups go adjuvant osi / alec instead.
PD-L1 TPS 50% is not “IO-mono exclusive” — IO-chemo data in fit patients are more consistent, especially for non-squamous.
Post-osi requires typing before treating — MET-amplified → SACHI, MET-overexpressing → teliso-v, broad-spectrum → MARIPOSA-2 or Dato-DXd.
KRAS G12C is still 2L only — do not use in 1L; 1L remains IO-chemo based on histology + PD-L1.
Perioperative therapy in 2026 is SoC that was unthinkable 5 years ago — 3-4 cycles of pre-op IO-chemo is the new starting point.
Chinese PD-1 accessibility × price: sintilimab / tislelizumab / camrelizumab / toripalimab are reasonable choices backed by their own phase III data but without H2H vs pembro. Insurance- and accessibility-driven decisions are the real-world norm.
AK112 (ivonescimab) may be the next breakthrough — but until global replication succeeds, treat it cautiously.

7. Sources

The 111-trial metadata in this report is independently verified via PubMed and ClinicalTrials.gov. Each [PMID xxxxxxxx] in the body can be opened directly on PubMed for verification.

Published trials: 111, covering 2002-2026
Ongoing phase III: 90 (primary completion 2025-2026)
FDA/NMPA 2024-2026 approvals: 20
2024-2025 key conference readouts: 21 (those with PMID available have been promoted to published trials)
Research gaps: 10

7.1 PMID Reference Table (ascending order)

The table below is the PMID list bracket-cited in the body; each can be clicked through to PubMed for verification.

PMID	Trial / Paper	Year	Journal	Section
11784875	ECOG 1594	2002	NEJM	§2.1 Chemo plateau
12837811	TAX 326	2003	JCO	§2.1
18506025	JMDB / Scagliotti 2008	2008	JCO	§2.1
19692680	IPASS	2009	NEJM	§2.2 EGFR TKI
21783417	OPTIMAL	2011	Lancet Oncol	§2.2
22285168	EURTAC	2012	Lancet Oncol	§2.2
22341744	PARAMOUNT	2012	Lancet Oncol	§2.1
25470694	PROFILE 1014	2014	NEJM	§2.3 ALK
26028407	CheckMate-017	2015	NEJM	§2.4 IO
26412456	CheckMate-057	2015	NEJM	§2.4
26712084	KEYNOTE-010	2016	Lancet	§2.4
27718847	KEYNOTE-024	2016	NEJM	§2.4, §3.1
28586279	ALEX	2017	NEJM	§2.3 ALK
28885881	PACIFIC	2017	NEJM	§2.2
29151359	FLAURA primary	2018	NEJM	§2.2
29658856	KEYNOTE-189 primary	2018	NEJM	§2.4, §3.1
29863955	IMpower150	2018	NEJM	§2.4, §3.1
30280635	KEYNOTE-407 primary	2018	NEJM	§2.4, §3.1
30955977	KEYNOTE-042	2019	Lancet	§3.1
31562796	CheckMate-227 primary	2019	NEJM	§2.4, §3.4
31751012	FLAURA OS	2019	NEJM	§2.2
32469185	VISION tepotinib	2020	NEJM	§2.3, §3.6
32877583	GEOMETRY mono-1 capmatinib	2020	NEJM	§2.3, §3.6
32955177	ADAURA primary	2020	NEJM	§2.2, §3.3
32997907	IMpower110	2020	NEJM	§2.4
33207094	CROWN primary	2020	NEJM	§2.3 ALK
33476593	CheckMate 9LA primary	2021	Lancet Oncol	§2.4, §3.1
33872070	KEYNOTE-024 5y	2021	JCO	§2.4
34096690	CodeBreaK 100	2021	NEJM	§2.3 KRAS
34555333	IMpower010 primary	2021	Lancet	§2.5, §3.3
35403841	CheckMate 816 primary	2022	NEJM	§2.5, §3.3
35917647	ORIENT-11 final OS	2022	JTO	§2.4
36108662	KEYNOTE-091	2022	Lancet Oncol	§2.5, §3.3
36223558	CheckMate-227 5y	2023	JCO	§2.4, §3.4
36327426	POSEIDON primary	2023	JCO	§2.4, §3.1, §3.4
36735893	KEYNOTE-407 5y	2023	JCO	§2.4, §3.1
36764316	CodeBreaK 200	2023	Lancet	§2.3 KRAS, §3.6
36809080	KEYNOTE-189 5y	2023	JCO	§2.4, §3.1, §3.4
37270692	PHAROS enco+bini	2023	JCO	§2.3 BRAF, §3.6
37272513	KEYNOTE-671 primary	2023	NEJM	§2.5, §3.3
37272535	ADAURA OS	2023	NEJM	§2.2, §3.3
37611121	Divarasib phase 1/2	2023	NEJM	§2.3 KRAS, §3.6
37689979	HERTHENA-Lung01	2023	JCO	§2.2, §3.5
37694347	DESTINY-Lung02	2023	JCO	§2.3 HER2, §3.6
37870973	LIBRETTO-431	2023	NEJM	§2.3 RET, §3.6
37870974	AEGEAN primary	2023	NEJM	§2.5, §3.3
37870976	PAPILLON	2023	NEJM	§2.3 EGFR ex20, §3.6
37879444	MARIPOSA-2	2024	Ann Oncol	§2.2, §3.5
37937763	FLAURA2 primary	2023	NEJM	§2.2, §3.2
38197815	TRIDENT-1	2024	NEJM	§2.3 ROS1, §3.6
38227033	Neotorch	2024	JAMA	§2.5, §3.3
38598794	ALINA	2024	NEJM	§2.3 ALK, §3.3
38749033	CheckMate 77T	2024	NEJM	§2.5, §3.3
38819031	CROWN 5y	2024	JCO	§3.6
38828946	LAURA	2024	NEJM	§2.2
38843488	LUMINOSITY teliso-v	2024	JCO	§2.2, §3.5
38924756	MARIPOSA primary	2024	NEJM	§2.2, §3.2
39243945	POSEIDON 5y	2025	JTO	§3.4
39250535	TROPION-Lung01	2025	JCO	§2.2, §3.5
39270380	CheckMate 9LA 5y	2024	JCO	§2.4
39288781	KEYNOTE-671 OS	2024	Lancet	§2.5, §3.3
39362249	GEOMETRY mono-1 final	2024	Lancet Oncol	§3.6
39581197	RATIONALE-315 interim	2025	Lancet Respir Med	§2.5, §3.3
40293180	Beamion LUNG-1 zongertinib	2025	NEJM	§2.3 HER2, §3.6
40446184	IMpower010 5y	2025	JCO	§3.3
40454642	CheckMate 816 OS	2025	NEJM	§2.5
40480428	PHAROS updated	2025	JCO	§3.6
40783289	KRYSTAL-12	2025	Lancet	§2.3 KRAS, §3.6
40923797	MARIPOSA OS	2025	NEJM	§2.2, §3.2
41104938	FLAURA2 OS	2026	NEJM	§2.2, §3.2
41486797	2025 NMA pembro+chemo	2025	Tuberk Toraks	§3.1
41544643	SACHI	2026	Lancet	§2.2, §3.2, §3.5

7.2 Verification

Every PMID is directly accessible via https://pubmed.ncbi.nlm.nih.gov/{PMID}/
Every NCT id via https://clinicaltrials.gov/study/{NCT_id}/
If you find a discrepancy between a PMID in this report and its PubMed entry (trial name / year / conclusion), please flag it for correction.

Closing

NSCLC over the past 25 years has been oncology’s most rapidly changing field — from four-way-tied chemo doublets in 2002 to 10 drivers × 3 IO strategies × the perioperative matrix in 2026, decision-making complexity has grown exponentially.

The flip side of complexity is precision. The “possible median OS” a newly diagnosed stage IV NSCLC patient can now expect has moved from ~8 months in 2002 to ~47 months in EGFRm (FLAURA2 final OS), ~12 months + ADC in HER2 ex20, ~34 months + repotrectinib in ROS1, and 30% more cure in resectable disease via perioperative therapy.

This report’s value is not in exhaustively listing every trial (PubMed does that) but in compressing 25 years of evolution + current decisions + unsolved gaps into the cognitive bandwidth of a single read. The next time you face a newly diagnosed NSCLC patient, every branch of the decision tree has this map to consult, trace, and question.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-17

Perioperative on Dual Brain Lab

Esophageal Cancer Trial Timeline: A Dual-Track Map of 30 Years and 42 RCTs

Esophageal Cancer Clinical Trial Timeline — In-Depth Report

1. One-sentence definition

2. Longitudinal: five paradigm shifts along the timeline

2.1 Definitive CRT era established (1992–2007): making “no surgery” an option, and the dose paradox

2.2 Global neoadjuvant CRT (2012–2018): CROSS rewrote the world + East Asia split off

2.3 Intra–East Asia ESCC divergence (2024): JCOG1109 NExT broke the “RT always helps” assumption

2.4 Advanced IO big three explosion (2019–2024): 4 years and 8 positive phase III trials reset SoC from CF/TP to IO+chemo

2.5 IO enters the perioperative setting (2021–2024): CheckMate-577 adjuvant rewrote + ESCORT-NEO neo-adj established

2.6 Surgical technique and local therapy (2012–2020): MIE / RAMIE / proton vs IMRT

2.7 EGFR death in ESCC (2017–2020): POWER + SCOPE-1

3. Cross-sectional: 2026 decision landscape (six dimensions)

3.1 Newly diagnosed advanced ESCC 1L: 8 IO+chemo phase III trials in parallel, how to choose under fragmented PD-L1 metrics

3.2 Advanced EAC / GEJ AC 1L: KEYNOTE-590 all-comers + borrowing from gastric

3.3 Advanced 2L+: post-1L-IO is the largest ESCC clinical gap of the next 5 years

3.4 Perioperative LA-ESCC: East Asian three-country split + CheckMate-577 adjuvant global SoC

3.5 Unresectable LA ESCC def-CRT: 50 Gy + CF dose unchanged for 40 years + KN-975 pending

3.6 Surgical technique: MIE vs RAMIE vs open

4. Research Gaps: the ten unresolved clinical questions

5. 2024–2026 latest developments

5.1 Recent FDA / NMPA approvals (ESCC / EC-related excerpts)

5.2 Key conference readouts (2024–2026, flagged as lower-tier)

5.3 Ongoing phase III (selected 2026–2028 readouts)

6. Intersecting insights and judgments

6.1 Longitudinal × cross-sectional: the 2026 EC landscape is shaped by four “resonances”

6.2 Clinical decision takeaways (for junior-mid oncologists)

7. Sources

7.1 Citation index (sorted by PMID)

7.2 Verification conventions

The clinical trial timeline lives here

Closing

Gastric Cancer Clinical Trial Timeline: 58 RCTs Across 25 Years Mapping a Subtyping Revolution

Gastric Cancer Clinical Trial Timeline — In-depth Report

1. One-sentence definition

2. Longitudinal: timeline of five treatment-paradigm shifts

2.1 Chemotherapy backbone era (2001-2010): adjuvant chemoRT / perioperative chemo / HER2 — three starting points

2.2 East–West adjuvant / perioperative divergence takes shape (2010-2019): CLASSIC / FLOT4 / ARTIST / RESOLVE / PRODIGY

2.3 HER2 era’s 10-year leap (2010-2025): ToGA → T-DXd → KEYNOTE-811 / zanidatamab

2.4 IO + chemo 1L rewrite (2021-2024): four phase IIIs concordantly positive

2.5 Biomarker triple-subtype year zero + perioperative IO + CAR-T dawn (2023-2026)

3. Horizontal: the 2026 decision landscape (six dimensions)

3.1 Newly diagnosed advanced GC/GEJ: full biomarker four-panel

3.2 Advanced 1L landscape: four PD-(L)1 class effect + CPS threshold policy divergence

3.3 Advanced 2L+: HER2 status dominates + mandatory re-biopsy

3.4 Adjuvant / perioperative: five East–West paths that never meet

3.5 Perioperative IO: MATTERHORN positive + key lessons

3.6 Surgical technique: D2 + laparoscopic consensus + robotic undecided

4. Research Gaps: ten unsolved clinical questions

5. Latest 2024-2026 developments

5.1 FDA / NMPA new approvals (gastric-relevant excerpts)

5.2 Key meeting readouts (2025-2026, flagged as lower-weight)

5.3 Ongoing phase IIIs (2026-2028 readout highlights)

6. Synthesis insights and judgments

6.1 Longitudinal × horizontal: 2026 gastric landscape shaped by three subtyping revolutions

6.2 Clinical decision takeaways (for junior-mid oncologists)

7. Information sources

7.1 Text citation list (by ascending PMID)

7.2 Verification conventions

Clinical trial timeline here

Closing

NSCLC Clinical Trial Timeline · 25-Year Evolution Map

NSCLC Clinical Trial Timeline · In-depth Report

1. One-Sentence Definition

2. Longitudinal: Five-Paradigm Evolution Timeline

2.1 Chemotherapy Plateau (2002–2015): Established, Challenged, Replaced

2.2 EGFR TKI Era (2009–2026): 2L → 1L → Adjuvant → Unresectable III → Combo

2.3 Non-EGFR Drivers (2014–2026): From Basket to Dedicated 1L

2.4 IO 1L (2015–2024): From 2L Trials to Backbone Rewrite

2.5 Perioperative IO (2021–2026): From Adjuvant-Only to Dual-Punch

3. Cross-Sectional: 2026 Decision Landscape (Six Dimensions)

3.1 1L IO-combo Selection (EGFR/ALK-WT, PD-L1 ≥1%)

3.2 EGFRm 1L: Three-Way Fight Between Mono and Combo

3.3 Perioperative IO: Choosing Among Three Strategies

3.4 PD-L1 TPS <1% Subgroup

3.5 EGFR / ALK Post-Resistance

3.6 Rare Drivers: 1L Entry Status for 8 Branches

4. Research Gaps: 10 Unsolved Clinical Questions

5. 2024–2026 Updates

5.1 FDA / NMPA New Approvals (10 key entries of 20)